Trial Outcomes & Findings for A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C (NCT NCT01675427)
NCT ID: NCT01675427
Last Updated: 2015-08-26
Results Overview
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype (Genotype 1 \[G1\], Genotype 2 \[G2\], Genotype 3 \[G3\], Genotype 4 \[G4\], and all other genotypes \[Other\]) and cirrhosis status ('Cirrhosis/transition to cirrhosis' or 'No cirrhosis') were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
4766 participants
Primary outcome timeframe
Study Visit 1 (single study visit)
Results posted on
2015-08-26
Participant Flow
Participant milestones
| Measure |
Participants With Chronic Hepatitis C (CHC)
Both treatment-naive and treatment-experienced participants with CHC were enrolled in this prospective, interventional Phase 4 study.
|
|---|---|
|
Overall Study
STARTED
|
4766
|
|
Overall Study
COMPLETED
|
4732
|
|
Overall Study
NOT COMPLETED
|
34
|
Reasons for withdrawal
| Measure |
Participants With Chronic Hepatitis C (CHC)
Both treatment-naive and treatment-experienced participants with CHC were enrolled in this prospective, interventional Phase 4 study.
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
7
|
|
Overall Study
Participant Refused Sample Collection
|
18
|
|
Overall Study
Sample not Collected by Mistake
|
2
|
|
Overall Study
Lost to Follow-up
|
5
|
|
Overall Study
Other
|
2
|
Baseline Characteristics
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Baseline characteristics by cohort
| Measure |
Participants With CHC
n=4616 Participants
Both treatment-naive and treatment-experienced participants with CHC were enrolled in this prospective, interventional Phase 4 study.
|
|---|---|
|
Age, Continuous
|
49.1 years
STANDARD_DEVIATION 12.87 • n=99 Participants
|
|
Sex: Female, Male
Female
|
2043 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
2573 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Study Visit 1 (single study visit)Population: Core Analysis Population (Treatment-Naive): Only participants who had not received prior treatment for CHC were included in the analysis; n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype (Genotype 1 \[G1\], Genotype 2 \[G2\], Genotype 3 \[G3\], Genotype 4 \[G4\], and all other genotypes \[Other\]) and cirrhosis status ('Cirrhosis/transition to cirrhosis' or 'No cirrhosis') were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=976 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1511 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=415 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G1, Cirrhosis (n=499,928,269)
|
111 participants
|
255 participants
|
87 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G1, No cirrhosis (n=499,928,269)
|
388 participants
|
673 participants
|
182 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G2, Cirrhosis (n=126,157,37)
|
23 participants
|
27 participants
|
3 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G2, No cirrhosis (n=126,157,37)
|
103 participants
|
130 participants
|
34 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G3, Cirrhosis (n=231,276,65)
|
76 participants
|
67 participants
|
18 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G3, No cirrhosis (n=231,276,65)
|
155 participants
|
209 participants
|
47 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G4, Cirrhosis (n=92,129,38)
|
29 participants
|
35 participants
|
10 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
G4, No cirrhosis (n=92,129,38)
|
63 participants
|
94 participants
|
28 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
Other, Cirrhosis (n=28,21,6)
|
9 participants
|
6 participants
|
1 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
Other, No cirrhosis (n=28,21,6)
|
19 participants
|
15 participants
|
5 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
Total, Cirrhosis (n=976,1511,415)
|
248 participants
|
390 participants
|
119 participants
|
|
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
Total, No cirrhosis (n=976,1511,415)
|
728 participants
|
1121 participants
|
296 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced): Only participants who had received prior treatment for CHC were included in the analysis; n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=462 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=850 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=275 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G1, Cirrhosis (n=281,653,226)
|
93 participants
|
208 participants
|
67 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G2, Cirrhosis (n=89,36,9)
|
30 participants
|
8 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G3, Cirrhosis (n=55,75,19)
|
19 participants
|
26 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G3, No cirrhosis (n=55,75,19)
|
36 participants
|
49 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Other, Cirrhosis (n=12,20,2)
|
6 participants
|
7 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Other, No cirrhosis (n=12,20,2)
|
6 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G1, No cirrhosis (n=281,653,226)
|
188 participants
|
445 participants
|
159 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G2, No cirrhosis (n=89,36,9)
|
59 participants
|
28 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G4, Cirrhosis (n=25,66,19)
|
4 participants
|
15 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G4, No cirrhosis (n=25,66,19)
|
21 participants
|
51 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Total, Cirrhosis (n=462,850,275)
|
152 participants
|
264 participants
|
81 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Total, No cirrhosis (n=462,850,275)
|
310 participants
|
586 participants
|
194 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1593 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1141 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=168 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G2, No cirrhosis (n=197,111,12)
|
164 participants
|
92 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G3, Cirrhosis (n=360,185,27)
|
111 participants
|
42 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G3, No cirrhosis (n=360,185,27)
|
249 participants
|
143 participants
|
19 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G4, No cirrhosis (n=164,85,10)
|
119 participants
|
59 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
Other, Cirrhosis (n=37,15,3)
|
11 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
Total, Cirrhosis (n=1593,1141,168)
|
400 participants
|
309 participants
|
48 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
Total, No cirrhosis (n=1593,1141,168)
|
1193 participants
|
832 participants
|
120 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G1, Cirrhosis (n=835,745,116)
|
200 participants
|
217 participants
|
36 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G1, No cirrhosis (n=835,745,116)
|
635 participants
|
528 participants
|
80 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G2, Cirrhosis (n=197,111,12)
|
33 participants
|
19 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
G4, Cirrhosis (n=164,85,10)
|
45 participants
|
26 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
Other, No cirrhosis (n=37,15,3)
|
26 participants
|
10 participants
|
3 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=796 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=682 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=109 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G1, Cirrhosis (n=528,539,93)
|
158 participants
|
179 participants
|
31 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G1, No cirrhosis (n=528,539,93)
|
370 participants
|
360 participants
|
62 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G2, Cirrhosis (n=102,25,7)
|
35 participants
|
3 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G2, No cirrhosis (n=102,25,7)
|
67 participants
|
22 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G4, Cirrhosis (n=70,40,0)
|
11 participants
|
13 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G4, No cirrhosis (n=70,40,0)
|
59 participants
|
27 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Other, Cirrhosis (n=15,19,0)
|
8 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Other, No cirrhosis (n=15,19,0)
|
7 participants
|
14 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G3, Cirrhosis (n=81,59,9)
|
29 participants
|
19 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
G3, No cirrhosis (n=81,59,9)
|
52 participants
|
40 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Total, Cirrhosis (n=796,682,109)
|
241 participants
|
219 participants
|
37 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Total, No cirrhosis (n=796,682,109)
|
555 participants
|
463 participants
|
72 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=331 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=465 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=126 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Cirrhotic (n=207,324,91)
|
10 participants
|
17 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Transition (n=207,324,91)
|
28 participants
|
40 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Advanced (n=207,324,91)
|
51 participants
|
88 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Mild (n=207,324,91)
|
101 participants
|
140 participants
|
34 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, No fibrosis (n=207,324,91)
|
17 participants
|
39 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Cirrhotic (n=24,25,5)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Transition (n=24,25,5)
|
3 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Advanced (n=24,25,5)
|
9 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Mild (n=24,25,5)
|
11 participants
|
13 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, No fibrosis (n=24,25,5)
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Cirrhotic (n=67,65,16)
|
8 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Transition (n=67,65,16)
|
12 participants
|
3 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Advanced (n=67,65,16)
|
13 participants
|
12 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Mild (n=67,65,16)
|
28 participants
|
32 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, No fibrosis (n=67,65,16)
|
6 participants
|
12 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Cirrhotic (n=28,48,12)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Transition (n=28,48,12)
|
4 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Advanced (n=28,48,12)
|
6 participants
|
14 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Mild (n=28,48,12)
|
15 participants
|
21 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, No fibrosis (n=28,48,12)
|
2 participants
|
7 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Cirrhotic (n=5,3,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Transition (n=5,3,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Advanced (n=5,3,2)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Mild (n=5,3,2)
|
0 participants
|
2 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, No fibrosis (n=5,3,2)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Cirrhotic (n=331,465,126)
|
21 participants
|
25 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Transition (n=331,465,126)
|
48 participants
|
52 participants
|
23 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Advanced (n=331,465,126)
|
81 participants
|
119 participants
|
22 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Mild (n=331,465,126)
|
155 participants
|
208 participants
|
51 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, No fibrosis (n=331,465,126)
|
26 participants
|
61 participants
|
15 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=277 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=511 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=164 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Mild (n=277,511,164)
|
84 participants
|
173 participants
|
57 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, No fibrosis (n=277,511,164)
|
22 participants
|
48 participants
|
20 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Cirrhotic (n=186,422,141)
|
20 participants
|
41 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Transition (n=186,422,141)
|
35 participants
|
86 participants
|
26 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Advanced (n=186,422,141)
|
63 participants
|
111 participants
|
40 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Mild (n=186,422,141)
|
55 participants
|
141 participants
|
50 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, No fibrosis (n=186,422,141)
|
13 participants
|
43 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Cirrhotic (n=49,11,5)
|
5 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Transition (n=49,11,5)
|
9 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Advanced (n=49,11,5)
|
15 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Mild (n=49,11,5)
|
15 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, No fibrosis (n=49,11,5)
|
5 participants
|
0 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Cirrhotic (n=26,31,7)
|
5 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Transition (n=26,31,7)
|
3 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Advanced (n=26,31,7)
|
8 participants
|
5 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Mild (n=26,31,7)
|
8 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, No fibrosis (n=26,31,7)
|
2 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Cirrhotic (n=9,35,10)
|
0 participants
|
6 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Transition (n=9,35,10)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Advanced (n=9,35,10)
|
2 participants
|
17 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Mild (n=9,35,10)
|
4 participants
|
9 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, No fibrosis (n=9,35,10)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Cirrhotic (n=7,12,1)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Transition (n=7,12,1)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Advanced (n=7,12,1)
|
0 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Mild (n=7,12,1)
|
2 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, No fibrosis (n=7,12,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Cirrhotic (n=277,511,164)
|
32 participants
|
54 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Transition (n=277,511,164)
|
51 participants
|
96 participants
|
28 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Advanced (n=277,511,164)
|
88 participants
|
140 participants
|
47 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=527 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=343 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=52 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Cirrhotic (n=331,252,39)
|
20 participants
|
16 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Transition (n=331,252,39)
|
44 participants
|
34 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Advanced (n=331,252,39)
|
89 participants
|
62 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Mild (n=331,252,39)
|
145 participants
|
110 participants
|
20 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, No fibrosis (n=331,252,39)
|
33 participants
|
30 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Cirrhotic (n=33,19,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Transition (n=33,19,2)
|
5 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Advanced (n=33,19,2)
|
10 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Mild (n=33,19,2)
|
17 participants
|
10 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, No fibrosis (n=33,19,2)
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Cirrhotic (n=98,42,8)
|
13 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Transition (n=98,42,8)
|
15 participants
|
2 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Advanced (n=98,42,8)
|
18 participants
|
10 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Mild (n=98,42,8)
|
40 participants
|
22 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, No fibrosis (n=98,42,8)
|
12 participants
|
7 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Cirrhotic (n=59,27,2)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Transition (n=59,27,2)
|
5 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Advanced (n=59,27,2)
|
14 participants
|
7 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Mild (n=59,27,2)
|
32 participants
|
11 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, No fibrosis (n=59,27,2)
|
6 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Cirrhotic (n=6,3,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Transition (n=6,3,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Advanced (n=6,3,1)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Mild (n=6,3,1)
|
1 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, No fibrosis (n=6,3,1)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Cirrhotic (n=527,343,52)
|
37 participants
|
18 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Transition (n=527,343,52)
|
70 participants
|
43 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Advanced (n=527,343,52)
|
133 participants
|
83 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Mild (n=527,343,52)
|
235 participants
|
155 participants
|
24 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, No fibrosis (n=527,343,52)
|
52 participants
|
44 participants
|
6 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=468 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=415 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=69 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Cirrhotic (n=332,356,61)
|
34 participants
|
32 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Transition (n=332,356,61)
|
58 participants
|
74 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Advanced (n=332,356,61)
|
109 participants
|
92 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Mild (n=332,356,61)
|
106 participants
|
119 participants
|
21 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, No fibrosis (n=332,356,61)
|
25 participants
|
39 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Cirrhotic (n=52,9,4)
|
6 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Transition (n=52,9,4)
|
10 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Advanced (n=52,9,4)
|
15 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Mild (n=52,9,4)
|
16 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, No fibrosis (n=52,9,4)
|
5 participants
|
0 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Cirrhotic (n=38,22,4)
|
6 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Transition (n=38,22,4)
|
5 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Advanced (n=38,22,4)
|
9 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Mild (n=38,22,4)
|
13 participants
|
9 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, No fibrosis (n=38,22,4)
|
5 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Cirrhotic (n=37,17,0)
|
4 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Transition (n=37,17,0)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Advanced (n=37,17,0)
|
18 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Mild (n=37,17,0)
|
10 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, No fibrosis (n=37,17,0)
|
3 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Cirrhotic (n=9,11,0)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Transition (n=9,11,0)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Advanced (n=9,11,0)
|
1 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, No fibrosis (n=9,11,0)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Cirrhotic (n=468,415,69)
|
52 participants
|
41 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Transition (n=468,415,69)
|
78 participants
|
80 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Advanced (n=468,415,69)
|
152 participants
|
108 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Mild (n=468,415,69)
|
147 participants
|
145 participants
|
22 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, No fibrosis (n=468,415,69)
|
39 participants
|
41 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Mild (n=9,11,0)
|
2 participants
|
6 participants
|
0 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=166 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=249 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=77 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F0 (n=95,177,56)
|
6 participants
|
20 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F1 (n=95,177,56)
|
33 participants
|
63 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F2 (n=95,177,56)
|
34 participants
|
57 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F3 (n=95,177,56)
|
16 participants
|
23 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F4 (n=95,177,56)
|
6 participants
|
14 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F1 (n=15,11,2)
|
6 participants
|
5 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F2 (n=15,11,2)
|
6 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F3 (n=15,11,2)
|
2 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F4 (n=15,11,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F0 (n=31,26,9)
|
0 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F1 (n=31,26,9)
|
8 participants
|
10 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F2 (n=31,26,9)
|
9 participants
|
7 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F3 (n=31,26,9)
|
7 participants
|
2 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F4 (n=31,26,9)
|
7 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F0 (n=21,35,8)
|
2 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F1 (n=21,35,8)
|
12 participants
|
12 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F2 (n=21,35,8)
|
4 participants
|
13 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F3 (n=21,35,8)
|
3 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F0 (n=4,0,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F1 (n=4,0,2)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F2 (n=4,0,2)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F3 (n=4,0,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F4 (n=4,0,2)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F0 (n=166,249,77)
|
9 participants
|
29 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F1 (n=166,249,77)
|
59 participants
|
90 participants
|
27 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F2 (n=166,249,77)
|
55 participants
|
79 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F3 (n=166,249,77)
|
29 participants
|
32 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F4 (n=166,249,77)
|
14 participants
|
19 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F0 (n=15,11,2)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F4 (n=21,35,8)
|
0 participants
|
1 participants
|
0 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=174 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=322 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=86 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F0 (n=119,259,70)
|
7 participants
|
20 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F1 (n=119,259,70)
|
28 participants
|
61 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F2 (n=119,259,70)
|
44 participants
|
83 participants
|
31 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F4 (n=119,259,70)
|
14 participants
|
33 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F0 (n=31,7,1)
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F1 (n=31,7,1)
|
11 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F2 (n=31,7,1)
|
9 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F3 (n=31,7,1)
|
6 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F4 (n=31,7,1)
|
4 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F0 (n=16,23,5)
|
1 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F1 (n=16,23,5)
|
3 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F0 (n=5,30,9)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F1 (n=5,30,9)
|
1 participants
|
7 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F2 (n=5,30,9)
|
2 participants
|
16 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F3 (n=5,30,9)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F4 (n=5,30,9)
|
0 participants
|
5 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F0 (n=3,3,1)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F1 (n=3,3,1)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F2 (n=3,3,1)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F3 (n=3,3,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F4 (n=3,3,1)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F0 (n=174,322,86)
|
9 participants
|
23 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F1 (n=174,322,86)
|
44 participants
|
80 participants
|
19 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F2 (n=174,322,86)
|
61 participants
|
108 participants
|
37 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F3 (n=174,322,86)
|
36 participants
|
67 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F4 (n=174,322,86)
|
24 participants
|
44 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F3 (n=119,259,70)
|
26 participants
|
62 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F2 (n=16,23,5)
|
6 participants
|
5 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F3 (n=16,23,5)
|
1 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F4 (n=16,23,5)
|
5 participants
|
4 participants
|
0 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=277 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=187 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=28 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F0 (n=168,139,21)
|
13 participants
|
16 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F1 (n=168,139,21)
|
59 participants
|
45 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F2 (n=168,139,21)
|
59 participants
|
43 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F3 (n=168,139,21)
|
22 participants
|
22 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G1, Stage F4 (n=168,139,21)
|
15 participants
|
13 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F0 (n=20,7,1)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F1 (n=20,7,1)
|
10 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F2 (n=20,7,1)
|
6 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F3 (n=20,7,1)
|
3 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G2, Stage F4 (n=20,7,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F1 (n=42,20,4)
|
10 participants
|
9 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F2 (n=42,20,4)
|
11 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F3 (n=42,20,4)
|
9 participants
|
2 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F4 (n=42,20,4)
|
10 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F0 (n=43,20,1)
|
6 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F1 (n=43,20,1)
|
22 participants
|
7 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F2 (n=43,20,1)
|
11 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F3 (n=43,20,1)
|
4 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F0 (n=4,1,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F1 (n=4,1,1)
|
0 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F2 (n=4,1,1)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F3 (n=4,1,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Other, Stage F4 (n=4,1,1)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F0 (n=277,187,28)
|
22 participants
|
21 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F1 (n=277,187,28)
|
101 participants
|
64 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F2 (n=277,187,28)
|
89 participants
|
57 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F4 (n=277,187,28)
|
26 participants
|
15 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G3, Stage F0 (n=42,20,4)
|
2 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
G4, Stage F4 (n=43,20,1)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Total, Stage F3 (n=277,187,28)
|
39 participants
|
30 participants
|
6 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=291 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=256 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=35 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F0 (n=200,217,31)
|
14 participants
|
18 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F1 (n=200,217,31)
|
46 participants
|
50 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F3 (n=200,217,31)
|
45 participants
|
48 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F4 (n=200,217,31)
|
21 participants
|
27 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F0 (n=33,5,1)
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F1 (n=33,5,1)
|
12 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F2 (n=33,5,1)
|
9 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F3 (n=33,5,1)
|
6 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G2, Stage F4 (n=33,5,1)
|
5 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F0 (n=25,16,3)
|
3 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F1 (n=25,16,3)
|
6 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F2 (n=25,16,3)
|
7 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F3 (n=25,16,3)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G3, Stage F4 (n=25,16,3)
|
6 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F0 (n=30,14,0)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F2 (n=30,14,0)
|
17 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F3 (n=30,14,0)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F4 (n=30,14,0)
|
3 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F1 (n=3,4,0)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F2 (n=3,4,0)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F3 (n=3,4,0)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F4 (n=3,4,0)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F2 (n=291,256,35)
|
107 participants
|
88 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F3 (n=291,256,35)
|
57 participants
|
51 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F4 (n=291,256,35)
|
36 participants
|
35 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Other, Stage F0 (n=3,4,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G1, Stage F2 (n=200,217,31)
|
74 participants
|
74 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
G4, Stage F1 (n=30,14,0)
|
7 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F0 (n=291,256,35)
|
19 participants
|
20 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Total, Stage F1 (n=291,256,35)
|
72 participants
|
62 participants
|
9 participants
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kilopascals (kPa).
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=324 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=517 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=140 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G1 (n=177,316,82)
|
9.61 kPa
Interval 8.51 to 10.7
|
10.2 kPa
Interval 9.22 to 11.1
|
12.6 kPa
Interval 10.3 to 15.0
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G2 (n=40,55,15)
|
11.1 kPa
Interval 7.26 to 14.9
|
7.69 kPa
Interval 6.65 to 8.72
|
7.15 kPa
Interval 4.35 to 9.94
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G3 (n=60,83,24)
|
11.7 kPa
Interval 9.45 to 14.0
|
9.3 kPa
Interval 7.82 to 10.8
|
8.99 kPa
Interval 6.14 to 11.8
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G4 (n=43,59,18)
|
11.4 kPa
Interval 7.54 to 15.3
|
13.4 kPa
Interval 10.4 to 16.5
|
11.1 kPa
Interval 5.85 to 16.4
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Other (n=4,4,1)
|
12.1 kPa
Interval 4.65 to 19.6
|
21.9 kPa
Interval -34.4 to 78.2
|
4.00 kPa
Confidence interval not presented because the analysis only included 1 participant.
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Total (n=324,517,140)
|
10.5 kPa
Interval 9.45 to 11.4
|
10.2 kPa
Interval 9.46 to 11.0
|
11.2 kPa
Interval 9.53 to 12.8
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=54 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=122 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=39 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G1 (n=27,84,32)
|
11.7 kPa
Interval 8.4 to 14.9
|
13.2 kPa
Interval 10.3 to 16.2
|
13.5 kPa
Interval 9.69 to 17.4
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G2 (n=6,10,0)
|
13.3 kPa
Interval 6.37 to 20.2
|
5.11 kPa
Interval 4.06 to 6.16
|
8.17 kPa
Interval 5.14 to 11.2
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G3 (n=15,14,4)
|
12.3 kPa
Interval 6.57 to 18.1
|
8.64 kPa
Interval 5.22 to 12.1
|
9.48 kPa
Interval 0.708 to 18.2
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G4 (n=6,14,3)
|
10.7 kPa
Interval -2.17 to 23.5
|
10.6 kPa
Interval 6.16 to 15.0
|
8.9 kPa
Interval -0.589 to 18.4
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Other (n=0,0,0)
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Total (n=54,122,39)
|
11.9 kPa
Interval 9.46 to 14.4
|
11.7 kPa
Interval 9.61 to 13.9
|
12.8 kPa
Interval 9.54 to 16.0
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=528 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=404 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=49 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G1 (n=287,259,29)
|
9.46 kPa
Interval 8.61 to 10.3
|
10.9 kPa
Interval 9.78 to 12.1
|
13.7 kPa
Interval 9.77 to 17.6
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G2 (n=63,42,5)
|
9.44 kPa
Interval 6.96 to 11.9
|
7.95 kPa
Interval 6.73 to 9.18
|
8.76 kPa
Interval -1.92 to 19.4
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G3 (n=100,57,10)
|
11.4 kPa
Interval 9.67 to 13.2
|
8.45 kPa
Interval 7.3 to 9.6
|
6.51 kPa
Interval 2.86 to 10.2
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G4 (n=72,44,4)
|
11.2 kPa
Interval 8.63 to 13.8
|
14.2 kPa
Interval 10.2 to 18.2
|
13.7 kPa
Interval -9.32 to 36.6
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Total (n=528,404,49)
|
10.1 kPa
Interval 9.34 to 10.8
|
10.8 kPa
Interval 9.83 to 11.7
|
11.5 kPa
Interval 8.7 to 14.3
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Other (n=6,2,1)
|
9.32 kPa
Interval 3.4 to 15.2
|
40.1 kPa
Interval -403.0 to 484.0
|
4.00 kPa
Confidence interval not presented because the analysis only included 1 participant.
|
PRIMARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=97 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=103 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=15 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G1 (n=53,77,13)
|
12.7 kPa
Interval 9.89 to 15.5
|
13.7 kPa
Interval 10.6 to 16.9
|
10.2 kPa
Interval 7.0 to 13.4
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G2 (n=9,7,0)
|
10.5 kPa
Interval 5.31 to 15.6
|
5.21 kPa
Interval 3.71 to 6.72
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G3 (n=21,10,2)
|
12.1 kPa
Interval 7.7 to 16.4
|
7.82 kPa
Interval 5.0 to 10.6
|
5.95 kPa
Interval -8.66 to 20.6
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Total (n=97,103,15)
|
11.9 kPa
Interval 10.0 to 13.8
|
12.4 kPa
Interval 9.91 to 14.8
|
9.62 kPa
Interval 6.79 to 12.5
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G4 (n=14,9,0)
|
9.74 kPa
Interval 4.76 to 14.7
|
11.4 kPa
Interval 4.95 to 17.8
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Other (n=0,0,0)
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
NA kPa
The total number of participants analyzed in this arm/group by category was 0.
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=127 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=184 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=61 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A0 (n=76,132,46)
|
1 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A0 (n=8,4,0)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A1 (n=8,4,0)
|
4 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A3 (n=8,4,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A2 (n=21,34,8)
|
7 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A3 (n=21,34,8)
|
1 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A2 (n=4,0,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A3 (n=4,0,2)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A0 (n=127,184,61)
|
2 participants
|
11 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A1 (n=127,184,61)
|
64 participants
|
84 participants
|
36 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A2 (n=127,184,61)
|
46 participants
|
67 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A3 (n=127,184,61)
|
15 participants
|
22 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A1 (n=76,132,46)
|
38 participants
|
54 participants
|
24 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A2 (n=76,132,46)
|
27 participants
|
57 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A3 (n=76,132,46)
|
10 participants
|
17 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A2 (n=8,4,0)
|
4 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A0 (n=18,14,5)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A1 (n=18,14,5)
|
6 participants
|
7 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A2 (n=18,14,5)
|
7 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A3 (n=18,14,5)
|
4 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A0 (n=21,34,8)
|
0 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A1 (n=21,34,8)
|
13 participants
|
22 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A0 (n=4,0,2)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A1 (n=4,0,2)
|
3 participants
|
0 participants
|
2 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=149 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=249 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=73 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A2 (n=102,203,60)
|
48 participants
|
90 participants
|
32 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A3 (n=102,203,60)
|
18 participants
|
29 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A0 (n=28,7,1)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A2 (n=28,7,1)
|
15 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A3 (n=28,7,1)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A2 (n=11,7,4)
|
6 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A3 (n=11,7,4)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A2 (n=5,29,8)
|
3 participants
|
10 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A3 (n=5,29,8)
|
1 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A0 (n=3,3,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A2 (n=3,3,0)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A3 (n=3,3,0)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A0 (n=149,249,73)
|
4 participants
|
6 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A1 (n=149,249,73)
|
51 participants
|
103 participants
|
26 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A3 (n=149,249,73)
|
22 participants
|
34 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A0 (n=102,203,60)
|
3 participants
|
5 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A1 (n=102,203,60)
|
33 participants
|
79 participants
|
19 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A1 (n=28,7,1)
|
13 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A0 (n=11,7,4)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A1 (n=11,7,4)
|
3 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A0 (n=5,29,8)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A1 (n=5,29,8)
|
1 participants
|
15 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A1 (n=3,3,0)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A2 (n=149,249,73)
|
72 participants
|
106 participants
|
38 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=207 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=143 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=22 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A0 (n=127,109,18)
|
1 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A2 (n=127,109,18)
|
46 participants
|
45 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A3 (n=127,109,18)
|
17 participants
|
15 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A0 (n=11,1,0)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A1 (n=11,1,0)
|
5 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A2 (n=11,1,0)
|
6 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G2, Grade A3 (n=11,1,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A0 (n=22,13,2)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A1 (n=22,13,2)
|
9 participants
|
6 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A3 (n=22,13,2)
|
4 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A0 (n=43,19,1)
|
4 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A3 (n=43,19,1)
|
2 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A0 (n=4,1,1)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A1 (n=4,1,1)
|
3 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A2 (n=4,1,1)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Other, Grade A3 (n=4,1,1)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A0 (n=207,143,22)
|
6 participants
|
8 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A1 (n=207,143,22)
|
109 participants
|
64 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A2 (n=207,143,22)
|
69 participants
|
52 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Total, Grade A3 (n=207,143,22)
|
23 participants
|
19 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G1, Grade A1 (n=127,109,18)
|
63 participants
|
45 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G3, Grade A2 (n=22,13,2)
|
8 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A1 (n=43,19,1)
|
29 participants
|
12 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
G4, Grade A2 (n=43,19,1)
|
8 participants
|
2 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=235 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=205 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=31 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A1 (n=3,3,0)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A2 (n=3,3,0)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A0 (n=160,177,28)
|
4 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A1 (n=160,177,28)
|
52 participants
|
70 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A2 (n=160,177,28)
|
77 participants
|
79 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G1, Grade A3 (n=160,177,28)
|
27 participants
|
23 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A0 (n=30,5,1)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A1 (n=30,5,1)
|
14 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A3 (n=30,5,1)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A0 (n=14,6,2)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A1 (n=14,6,2)
|
4 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A0 (n=28,14,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A0 (n=3,3,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Other, Grade A3 (n=3,3,0)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A0 (n=235,205,31)
|
5 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A1 (n=235,205,31)
|
85 participants
|
85 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A2 (n=235,205,31)
|
110 participants
|
90 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Total, Grade A3 (n=235,205,31)
|
35 participants
|
24 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G2, Grade A2 (n=30,5,1)
|
16 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A2 (n=14,6,2)
|
7 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G3, Grade A3 (n=14,6,2)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A1 (n=28,14,0)
|
14 participants
|
7 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A2 (n=28,14,0)
|
10 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
G4, Grade A3 (n=28,14,0)
|
4 participants
|
1 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=978 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1518 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=420 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive
Male
|
582 participants
|
802 participants
|
224 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive
Female
|
396 participants
|
716 participants
|
196 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=490 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=914 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=296 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced
Male
|
287 participants
|
509 participants
|
169 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced
Female
|
203 participants
|
405 participants
|
127 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1598 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1147 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=171 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive
Male
|
910 participants
|
608 participants
|
90 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive
Female
|
688 participants
|
539 participants
|
81 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=851 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=730 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=119 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced
Male
|
489 participants
|
412 participants
|
64 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced
Female
|
362 participants
|
318 participants
|
55 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=978 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1518 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=420 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive
Caucasian/white
|
860 participants
|
1349 participants
|
373 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive
Black
|
5 participants
|
24 participants
|
19 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive
Asian/Oriental
|
89 participants
|
83 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive
Native American/American Indian
|
0 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive
Other
|
24 participants
|
61 participants
|
18 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=490 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=914 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=296 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced
Caucasian/white
|
314 participants
|
807 participants
|
259 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced
Black
|
3 participants
|
20 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced
Asian/Oriental
|
161 participants
|
42 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced
Native American/American Indian
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced
Other
|
12 participants
|
43 participants
|
17 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1598 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1147 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=171 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive
Caucasian/white
|
1402 participants
|
1030 participants
|
150 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive
Black
|
34 participants
|
12 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive
Asian/Oriental
|
123 participants
|
53 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive
Native American/American Indian
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive
Other
|
38 participants
|
52 participants
|
13 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=851 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=730 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=119 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced
Caucasian/white
|
628 participants
|
651 participants
|
101 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced
Black
|
31 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced
Asian/Oriental
|
172 participants
|
31 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced
Native American/American Indian
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced
Other
|
20 participants
|
40 participants
|
12 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kilograms (kg).
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=975 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1516 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=419 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Body Weight by IL28B Genotype rs12979860: Treatment-Naive
|
74.6 kg
Interval 73.7 to 75.6
|
74.4 kg
Interval 73.6 to 75.1
|
74.2 kg
Interval 72.7 to 75.6
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=489 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=913 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=296 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Body Weight by IL28B Genotype rs12979860: Treatment-Experienced
|
72.7 kg
Interval 71.4 to 73.9
|
75.0 kg
Interval 74.1 to 75.9
|
75.1 kg
Interval 73.5 to 76.7
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1594 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1145 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=171 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Body Weight by IL28B Genotype rs8099917: Treatment-Naive
|
74.8 kg
Interval 74.0 to 75.5
|
74.2 kg
Interval 73.4 to 75.0
|
72.8 kg
Interval 70.5 to 75.2
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=850 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=729 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=119 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Body Weight by IL28B Genotype rs8099917: Treatment-Experienced
|
73.7 kg
Interval 72.7 to 74.6
|
75.2 kg
Interval 74.2 to 76.2
|
73.8 kg
Interval 71.2 to 76.4
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kilograms per meter-squared (kg/m\^2), and mean BMI was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=975 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1511 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=418 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Body Mass Index (BMI) by IL28B Genotype rs12979860: Treatment-Naive
|
25.8 kg/m^2
Interval 25.5 to 26.1
|
26.0 kg/m^2
Interval 25.8 to 26.3
|
26.0 kg/m^2
Interval 25.6 to 26.5
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=488 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=912 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=293 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
BMI by IL28B Genotype rs12979860: Treatment-Experienced
|
25.8 kg/m^2
Interval 25.5 to 26.2
|
26.4 kg/m^2
Interval 26.1 to 26.7
|
26.3 kg/m^2
Interval 25.8 to 26.8
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1592 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1141 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=171 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
BMI by IL28B Genotype rs8099917: Treatment-Naive
|
26.0 kg/m^2
Interval 25.7 to 26.2
|
26.0 kg/m^2
Interval 25.7 to 26.3
|
25.4 kg/m^2
Interval 24.8 to 26.1
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=848 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=727 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=118 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
BMI by IL28B Genotype rs8099917: Treatment-Experienced
|
26.0 kg/m^2
Interval 25.7 to 26.3
|
26.4 kg/m^2
Interval 26.1 to 26.7
|
26.4 kg/m^2
Interval 25.6 to 27.2
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=950 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1496 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=413 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive
G1
|
500 participants
|
930 participants
|
272 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive
G2
|
126 participants
|
160 participants
|
37 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive
G3
|
232 participants
|
277 participants
|
65 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive
G4
|
92 participants
|
129 participants
|
39 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=476 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=892 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=291 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced
G1
|
295 participants
|
703 participants
|
239 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced
G2
|
92 participants
|
38 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced
G3
|
63 participants
|
84 participants
|
20 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced
G4
|
26 participants
|
67 participants
|
21 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1561 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1131 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=167 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive
G1
|
837 participants
|
747 participants
|
118 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive
G2
|
198 participants
|
113 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive
G3
|
361 participants
|
186 participants
|
27 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive
G4
|
165 participants
|
85 participants
|
10 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=834 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=709 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=116 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced
G3
|
93 participants
|
65 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced
G4
|
71 participants
|
43 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced
G1
|
563 participants
|
574 participants
|
100 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced
G2
|
107 participants
|
27 participants
|
7 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 international units per milliliter (log10 IU/mL).
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=928 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1467 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=407 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G1 (n=481,903,263)
|
5.96 log10 IU/mL
Interval 5.87 to 6.06
|
5.89 log10 IU/mL
Interval 5.84 to 5.94
|
5.72 log10 IU/mL
Interval 5.63 to 5.82
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G2 (n=121,157,36)
|
5.95 log10 IU/mL
Interval 5.8 to 6.11
|
5.76 log10 IU/mL
Interval 5.61 to 5.92
|
5.92 log10 IU/mL
Interval 5.62 to 6.21
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G3 (n=226,268,63)
|
6.02 log10 IU/mL
Interval 5.89 to 6.15
|
5.81 log10 IU/mL
Interval 5.71 to 5.91
|
5.51 log10 IU/mL
Interval 5.3 to 5.71
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G4 (n=84,123,38)
|
5.68 log10 IU/mL
Interval 5.5 to 5.86
|
5.59 log10 IU/mL
Interval 5.46 to 5.73
|
5.45 log10 IU/mL
Interval 5.16 to 5.74
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Other (n=16,16,7)
|
5.46 log10 IU/mL
Interval 4.66 to 6.26
|
5.48 log10 IU/mL
Interval 4.87 to 6.08
|
5.58 log10 IU/mL
Interval 4.29 to 6.87
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Total (n=928,1467,407)
|
5.94 log10 IU/mL
Interval 5.88 to 6.01
|
5.83 log10 IU/mL
Interval 5.79 to 5.87
|
5.68 log10 IU/mL
Interval 5.6 to 5.76
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=382 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=744 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=240 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G1 (n=244,591,196)
|
6.06 log10 IU/mL
Interval 5.95 to 6.17
|
5.98 log10 IU/mL
Interval 5.92 to 6.03
|
5.84 log10 IU/mL
Interval 5.75 to 5.93
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G2 (n=68,30,10)
|
5.39 log10 IU/mL
Interval 5.13 to 5.65
|
6.07 log10 IU/mL
Interval 5.79 to 6.35
|
5.64 log10 IU/mL
Interval 5.0 to 6.29
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G3 (n=38,53,12)
|
5.97 log10 IU/mL
Interval 5.64 to 6.3
|
5.78 log10 IU/mL
Interval 5.52 to 6.05
|
5.60 log10 IU/mL
Interval 5.15 to 6.04
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Other (n=10,14,2)
|
5.59 log10 IU/mL
Interval 4.57 to 6.61
|
5.63 log10 IU/mL
Interval 5.17 to 6.1
|
4.90 log10 IU/mL
Interval 4.5 to 5.3
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Total (n=382,744,240)
|
5.89 log10 IU/mL
Interval 5.79 to 5.98
|
5.93 log10 IU/mL
Interval 5.88 to 5.98
|
5.80 log10 IU/mL
Interval 5.71 to 5.88
|
|
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G4 (n=22,56,20)
|
5.49 log10 IU/mL
Interval 5.12 to 5.87
|
5.58 log10 IU/mL
Interval 5.39 to 5.77
|
5.66 log10 IU/mL
Interval 5.31 to 6.0
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1529 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1108 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=165 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G1 (n=809,723,115)
|
5.99 log10 IU/mL
Interval 5.92 to 6.05
|
5.82 log10 IU/mL
Interval 5.76 to 5.87
|
5.61 log10 IU/mL
Interval 5.47 to 5.75
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G2 (n=191,111,12)
|
5.90 log10 IU/mL
Interval 5.76 to 6.03
|
5.74 log10 IU/mL
Interval 5.57 to 5.92
|
6.20 log10 IU/mL
Interval 5.8 to 6.59
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G4 (n=155,82,8)
|
5.64 log10 IU/mL
Interval 5.51 to 5.77
|
5.53 log10 IU/mL
Interval 5.35 to 5.71
|
5.53 log10 IU/mL
Interval 4.98 to 6.07
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Other (n=24,11,4)
|
5.53 log10 IU/mL
Interval 4.95 to 6.1
|
5.13 log10 IU/mL
Interval 4.24 to 6.01
|
6.27 log10 IU/mL
Interval 5.13 to 7.42
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Total (n=1529,1108,165)
|
5.93 log10 IU/mL
Interval 5.89 to 5.98
|
5.76 log10 IU/mL
Interval 5.71 to 5.81
|
5.63 log10 IU/mL
Interval 5.51 to 5.75
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G3 (n=350,181,26)
|
5.99 log10 IU/mL
Interval 5.88 to 6.09
|
5.69 log10 IU/mL
Interval 5.57 to 5.8
|
5.39 log10 IU/mL
Interval 5.1 to 5.68
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=679 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=594 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=93 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G1 (n=469,480,82)
|
6.04 log10 IU/mL
Interval 5.97 to 6.12
|
5.92 log10 IU/mL
Interval 5.86 to 5.97
|
5.85 log10 IU/mL
Interval 5.71 to 5.99
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G2 (n=81,21,6)
|
5.52 log10 IU/mL
Interval 5.29 to 5.75
|
5.97 log10 IU/mL
Interval 5.6 to 6.33
|
5.49 log10 IU/mL
Interval 4.39 to 6.58
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G3 (n=59,39,5)
|
5.87 log10 IU/mL
Interval 5.61 to 6.13
|
5.78 log10 IU/mL
Interval 5.47 to 6.1
|
5.73 log10 IU/mL
Interval 5.14 to 6.32
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G4 (n=59,39,0)
|
5.67 log10 IU/mL
Interval 5.49 to 5.85
|
5.43 log10 IU/mL
Interval 5.18 to 5.69
|
NA log10 IU/mL
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Other (n=11,15,0)
|
5.59 log10 IU/mL
Interval 4.68 to 6.49
|
5.54 log10 IU/mL
Interval 5.09 to 5.99
|
NA log10 IU/mL
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Total (n=679,594,93)
|
5.93 log10 IU/mL
Interval 5.86 to 5.99
|
5.87 log10 IU/mL
Interval 5.81 to 5.92
|
5.82 log10 IU/mL
Interval 5.68 to 5.96
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 international units per liter \[IU/L\] for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=955 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1480 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=416 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G1 (n=488,914,269)
|
2.09 ratio
Interval 1.92 to 2.27
|
1.77 ratio
Interval 1.68 to 1.86
|
1.63 ratio
Interval 1.47 to 1.79
|
|
Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G2 (n=123,152,37)
|
2.42 ratio
Interval 1.96 to 2.88
|
1.96 ratio
Interval 1.64 to 2.27
|
1.21 ratio
Interval 0.932 to 1.48
|
|
Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G3 (n=228,272,65)
|
2.80 ratio
Interval 2.52 to 3.08
|
2.32 ratio
Interval 2.09 to 2.55
|
2.05 ratio
Interval 1.64 to 2.45
|
|
Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G4 (n=88,121,38)
|
2.00 ratio
Interval 1.63 to 2.37
|
1.66 ratio
Interval 1.46 to 1.86
|
1.65 ratio
Interval 1.29 to 2.01
|
|
Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Other (n=28,21,7)
|
1.46 ratio
Interval 0.964 to 1.96
|
1.72 ratio
Interval 1.13 to 2.31
|
1.33 ratio
Interval 0.686 to 1.98
|
|
Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Total (n=955,1480,416)
|
2.28 ratio
Interval 2.14 to 2.41
|
1.88 ratio
Interval 1.8 to 1.96
|
1.65 ratio
Interval 1.53 to 1.78
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=398 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=686 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=229 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G1 (n=241,528,184)
|
3.00 ratio
Interval 2.69 to 3.32
|
2.14 ratio
Interval 2.0 to 2.29
|
2.00 ratio
Interval 1.75 to 2.25
|
|
Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G2 (n=80,32,9)
|
3.45 ratio
Interval 2.73 to 4.18
|
1.84 ratio
Interval 1.24 to 2.43
|
2.02 ratio
Interval 0.934 to 3.1
|
|
Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G3 (n=45,66,17)
|
3.06 ratio
Interval 2.55 to 3.58
|
2.49 ratio
Interval 2.03 to 2.96
|
2.27 ratio
Interval 1.38 to 3.16
|
|
Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G4 (n=23,47,17)
|
1.65 ratio
Interval 1.2 to 2.11
|
1.79 ratio
Interval 1.42 to 2.16
|
1.23 ratio
Interval 0.768 to 1.7
|
|
Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Other (n=9,13,2)
|
2.99 ratio
Interval 1.03 to 4.95
|
1.82 ratio
Interval 1.06 to 2.57
|
2.17 ratio
Interval -12.4 to 16.8
|
|
Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Total (n=398,686,229)
|
3.02 ratio
Interval 2.77 to 3.27
|
2.13 ratio
Interval 2.01 to 2.26
|
1.96 ratio
Interval 1.75 to 2.18
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1557 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1126 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=168 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G1 (n=818,737,116)
|
2.02 ratio
Interval 1.9 to 2.15
|
1.67 ratio
Interval 1.58 to 1.75
|
1.67 ratio
Interval 1.42 to 1.92
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G2 (n=192,108,12)
|
2.09 ratio
Interval 1.77 to 2.41
|
2.06 ratio
Interval 1.65 to 2.46
|
1.31 ratio
Interval 0.622 to 2.01
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G3 (n=355,183,27)
|
2.72 ratio
Interval 2.49 to 2.96
|
2.08 ratio
Interval 1.88 to 2.28
|
2.03 ratio
Interval 1.49 to 2.57
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G4 (n=155,83,9)
|
1.78 ratio
Interval 1.55 to 2.02
|
1.84 ratio
Interval 1.57 to 2.1
|
1.20 ratio
Interval 1.04 to 1.35
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Other (n=37,15,4)
|
1.66 ratio
Interval 1.2 to 2.12
|
1.25 ratio
Interval 0.803 to 1.69
|
1.56 ratio
Interval 0.139 to 2.99
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Total (n=1557,1126,168)
|
2.16 ratio
Interval 2.06 to 2.26
|
1.78 ratio
Interval 1.7 to 1.86
|
1.67 ratio
Interval 1.47 to 1.87
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=667 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=556 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=90 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G1 (n=442,437,74)
|
2.60 ratio
Interval 2.39 to 2.82
|
2.11 ratio
Interval 1.96 to 2.27
|
2.00 ratio
Interval 1.71 to 2.29
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G2 (n=92,23,6)
|
3.26 ratio
Interval 2.61 to 3.91
|
1.79 ratio
Interval 1.06 to 2.53
|
2.04 ratio
Interval 0.297 to 3.78
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G3 (n=68,51,9)
|
3.04 ratio
Interval 2.62 to 3.47
|
2.29 ratio
Interval 1.75 to 2.83
|
1.90 ratio
Interval 1.28 to 2.52
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G4 (n=54,33,0)
|
1.58 ratio
Interval 1.32 to 1.84
|
1.76 ratio
Interval 1.25 to 2.27
|
NA ratio
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Other (n=11,12,1)
|
2.78 ratio
Interval 1.18 to 4.38
|
1.75 ratio
Interval 0.949 to 2.54
|
3.32 ratio
Confidence interval not presented because the analysis only included 1 participant.
|
|
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Total (n=667,556,90)
|
2.66 ratio
Interval 2.48 to 2.84
|
2.09 ratio
Interval 1.95 to 2.23
|
2.01 ratio
Interval 1.75 to 2.27
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=940 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1444 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=405 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G1 (n=480,891,264)
|
1.62 ratio
Interval 1.51 to 1.73
|
1.59 ratio
Interval 1.51 to 1.66
|
1.46 ratio
Interval 1.34 to 1.58
|
|
Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G2 (n=122,151,37)
|
1.93 ratio
Interval 1.61 to 2.26
|
1.63 ratio
Interval 1.38 to 1.87
|
1.06 ratio
Interval 0.827 to 1.29
|
|
Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G3 (n=227,266,64)
|
2.17 ratio
Interval 2.0 to 2.35
|
1.88 ratio
Interval 1.69 to 2.07
|
1.44 ratio
Interval 1.21 to 1.67
|
|
Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G4 (n=83,118,33)
|
1.71 ratio
Interval 1.39 to 2.03
|
1.54 ratio
Interval 1.33 to 1.75
|
1.41 ratio
Interval 1.12 to 1.7
|
|
Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Other (n=28,18,7)
|
1.41 ratio
Interval 0.899 to 1.92
|
1.63 ratio
Interval 0.952 to 2.31
|
1.29 ratio
Interval 0.605 to 1.97
|
|
Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Total (n=940,1444,405)
|
1.80 ratio
Interval 1.71 to 1.89
|
1.64 ratio
Interval 1.57 to 1.71
|
1.41 ratio
Interval 1.32 to 1.5
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=391 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=655 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=218 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G1 (n=234,501,173)
|
2.27 ratio
Interval 2.02 to 2.51
|
1.78 ratio
Interval 1.66 to 1.9
|
1.65 ratio
Interval 1.48 to 1.83
|
|
Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G2 (n=80,32,9)
|
2.49 ratio
Interval 2.08 to 2.9
|
1.33 ratio
Interval 0.966 to 1.7
|
1.58 ratio
Interval 0.802 to 2.36
|
|
Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G3 (n=45,63,17)
|
2.42 ratio
Interval 1.98 to 2.87
|
2.07 ratio
Interval 1.65 to 2.5
|
1.71 ratio
Interval 1.09 to 2.32
|
|
Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G4 (n=23,46,17)
|
1.31 ratio
Interval 0.985 to 1.63
|
1.52 ratio
Interval 1.23 to 1.81
|
1.36 ratio
Interval 0.856 to 1.86
|
|
Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Other (n=9,13,2)
|
1.86 ratio
Interval 1.0 to 2.71
|
1.47 ratio
Interval 1.03 to 1.92
|
1.09 ratio
Interval -3.5 to 5.68
|
|
Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Total (n=391,655,218)
|
2.27 ratio
Interval 2.09 to 2.44
|
1.76 ratio
Interval 1.66 to 1.86
|
1.63 ratio
Interval 1.48 to 1.78
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1524 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1105 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=160 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G1 (n=800,724,111)
|
1.65 ratio
Interval 1.56 to 1.73
|
1.51 ratio
Interval 1.43 to 1.59
|
1.49 ratio
Interval 1.3 to 1.69
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G2 (n=190,108,12)
|
1.71 ratio
Interval 1.48 to 1.94
|
1.66 ratio
Interval 1.35 to 1.98
|
1.37 ratio
Interval 0.725 to 2.02
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G3 (n=350,181,26)
|
2.13 ratio
Interval 1.96 to 2.29
|
1.68 ratio
Interval 1.51 to 1.85
|
1.42 ratio
Interval 1.07 to 1.77
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G4 (n=148,79,7)
|
1.54 ratio
Interval 1.33 to 1.75
|
1.69 ratio
Interval 1.42 to 1.96
|
1.14 ratio
Interval 0.708 to 1.58
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Other (n=36,13,4)
|
1.41 ratio
Interval 0.996 to 1.82
|
1.62 ratio
Interval 0.707 to 2.54
|
1.51 ratio
Interval 0.0157 to 3.0
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Total (n=1524,1105,160)
|
1.75 ratio
Interval 1.68 to 1.82
|
1.57 ratio
Interval 1.5 to 1.64
|
1.46 ratio
Interval 1.3 to 1.61
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=647 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=531 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=86 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Other (n=11,12,1)
|
1.79 ratio
Interval 1.11 to 2.47
|
1.41 ratio
Interval 0.905 to 1.91
|
1.45 ratio
Confidence interval not presented because the analysis only included 1 participant.
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Total (n=647,531,86)
|
2.03 ratio
Interval 1.91 to 2.16
|
1.77 ratio
Interval 1.65 to 1.88
|
1.65 ratio
Interval 1.42 to 1.88
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G1 (n=423,415,70)
|
2.01 ratio
Interval 1.86 to 2.17
|
1.78 ratio
Interval 1.65 to 1.92
|
1.66 ratio
Interval 1.4 to 1.92
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G2 (n=92,23,6)
|
2.34 ratio
Interval 1.97 to 2.71
|
1.36 ratio
Interval 0.874 to 1.85
|
1.61 ratio
Interval 0.494 to 2.73
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G3 (n=67,49,9)
|
2.36 ratio
Interval 2.02 to 2.69
|
1.96 ratio
Interval 1.44 to 2.49
|
1.63 ratio
Interval 0.697 to 2.56
|
|
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G4 (n=54,32,0)
|
1.30 ratio
Interval 1.13 to 1.48
|
1.65 ratio
Interval 1.21 to 2.1
|
NA ratio
The total number of participants analyzed in this arm/group by category was 0.
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells per liter (10\^9 cells/L).
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=939 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1458 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=415 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G1 (n=483,900,269)
|
200 10^9 cells/L
Interval 195.0 to 205.0
|
204 10^9 cells/L
Interval 200.0 to 208.0
|
201 10^9 cells/L
Interval 194.0 to 208.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G2 (n=121,147,37)
|
190 10^9 cells/L
Interval 180.0 to 200.0
|
212 10^9 cells/L
Interval 201.0 to 222.0
|
203 10^9 cells/L
Interval 189.0 to 218.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G3 (n=225,268,64)
|
186 10^9 cells/L
Interval 180.0 to 193.0
|
201 10^9 cells/L
Interval 194.0 to 207.0
|
193 10^9 cells/L
Interval 182.0 to 204.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
G4 (n=85,124,38)
|
198 10^9 cells/L
Interval 185.0 to 211.0
|
191 10^9 cells/L
Interval 182.0 to 200.0
|
189 10^9 cells/L
Interval 177.0 to 201.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Other (n=25,19,7)
|
216 10^9 cells/L
Interval 169.0 to 263.0
|
203 10^9 cells/L
Interval 172.0 to 234.0
|
195 10^9 cells/L
Interval 165.0 to 225.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Total (n=939,1458,415)
|
196 10^9 cells/L
Interval 192.0 to 199.0
|
203 10^9 cells/L
Interval 200.0 to 206.0
|
199 10^9 cells/L
Interval 194.0 to 204.0
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=383 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=651 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=210 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G1 (n=233,501,167)
|
180 10^9 cells/L
Interval 173.0 to 186.0
|
196 10^9 cells/L
Interval 191.0 to 202.0
|
197 10^9 cells/L
Interval 189.0 to 205.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G3 (n=46,65,17)
|
182 10^9 cells/L
Interval 167.0 to 197.0
|
191 10^9 cells/L
Interval 176.0 to 206.0
|
191 10^9 cells/L
Interval 161.0 to 221.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G4 (n=22,43,17)
|
194 10^9 cells/L
Interval 180.0 to 208.0
|
184 10^9 cells/L
Interval 171.0 to 197.0
|
185 10^9 cells/L
Interval 161.0 to 209.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Other (n=8,13,1)
|
173. 10^9 cells/L
Interval 142.0 to 204.0
|
202 10^9 cells/L
Interval 150.0 to 255.0
|
209 10^9 cells/L
Confidence interval not presented because the analysis only included 1 participant.
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
G2 (n=74,29,8)
|
166 10^9 cells/L
Interval 154.0 to 178.0
|
181 10^9 cells/L
Interval 167.0 to 195.0
|
165 10^9 cells/L
Interval 102.0 to 228.0
|
|
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Total (n=383,651,210)
|
178 10^9 cells/L
Interval 173.0 to 183.0
|
194 10^9 cells/L
Interval 190.0 to 199.0
|
194 10^9 cells/L
Interval 187.0 to 202.0
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1538 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1106 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=168 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G1 (n=810,727,115)
|
200 10^9 cells/L
Interval 196.0 to 203.0
|
205 10^9 cells/L
Interval 200.0 to 210.0
|
203 10^9 cells/L
Interval 191.0 to 215.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G2 (n=188,105,12)
|
199 10^9 cells/L
Interval 190.0 to 207.0
|
209 10^9 cells/L
Interval 198.0 to 219.0
|
194 10^9 cells/L
Interval 158.0 to 229.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G3 (n=351,179,27)
|
191 10^9 cells/L
Interval 185.0 to 196.0
|
201 10^9 cells/L
Interval 193.0 to 208.0
|
196 10^9 cells/L
Interval 178.0 to 214.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
G4 (n=156,81,10)
|
195 10^9 cells/L
Interval 187.0 to 204.0
|
190 10^9 cells/L
Interval 178.0 to 202.0
|
185 10^9 cells/L
Interval 159.0 to 211.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Other (n=33,14,4)
|
216 10^9 cells/L
Interval 180.0 to 252.0
|
193 10^9 cells/L
Interval 157.0 to 229.0
|
199 10^9 cells/L
Interval 139.0 to 258.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Total (n=1538,1106,168)
|
197 10^9 cells/L
Interval 194.0 to 200.0
|
203 10^9 cells/L
Interval 200.0 to 207.0
|
200 10^9 cells/L
Interval 191.0 to 209.0
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=641 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=519 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=84 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G1 (n=426,406,69)
|
186 10^9 cells/L
Interval 181.0 to 192.0
|
199 10^9 cells/L
Interval 192.0 to 205.0
|
190 10^9 cells/L
Interval 180.0 to 200.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G2 (n=84,21,6)
|
167 10^9 cells/L
Interval 156.0 to 178.0
|
184 10^9 cells/L
Interval 157.0 to 210.0
|
162 10^9 cells/L
Interval 126.0 to 197.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G3 (n=68,51,9)
|
180 10^9 cells/L
Interval 168.0 to 191.0
|
199 10^9 cells/L
Interval 180.0 to 219.0
|
182 10^9 cells/L
Interval 149.0 to 214.0
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
G4 (n=53,29,0)
|
189 10^9 cells/L
Interval 178.0 to 200.0
|
182 10^9 cells/L
Interval 167.0 to 197.0
|
NA 10^9 cells/L
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Other (n=10,12,0)
|
194 10^9 cells/L
Interval 131.0 to 257.0
|
190 10^9 cells/L
Interval 155.0 to 226.0
|
NA 10^9 cells/L
The total number of participants analyzed in this arm/group by category was 0.
|
|
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Total (n=641,519,64)
|
183 10^9 cells/L
Interval 179.0 to 188.0
|
197 10^9 cells/L
Interval 192.0 to 202.0
|
187 10^9 cells/L
Interval 178.0 to 196.0
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=978 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1518 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=420 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G1, Asia (n=500,930,272)
|
16 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G1, Europe (n=500,930,272)
|
388 participants
|
680 participants
|
183 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G1, Middle East (n=500,930,272)
|
65 participants
|
167 participants
|
57 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G2, Middle East (n=126,160,37)
|
7 participants
|
12 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G2, Latin America (n=126,160,37)
|
4 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G3, Middle East (n=232,277,65)
|
8 participants
|
20 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G3, Latin America (n=232,277,65)
|
2 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G4, Asia (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G4, Europe (n=92,129,39)
|
37 participants
|
64 participants
|
27 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G4, Middle East (n=92,129,39)
|
53 participants
|
62 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G4, Latin America (n=92,129,39)
|
2 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Other, Asia (n=28,22,7)
|
13 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Other, Europe (n=28,22,7)
|
8 participants
|
7 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Other, Middle East (n=28,22,7)
|
5 participants
|
11 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Total, Asia (n=978,1518,420)
|
78 participants
|
66 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Total, Europe (n=978,1518,420)
|
721 participants
|
1095 participants
|
303 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Total, Middle East (n=978,1518,420)
|
138 participants
|
272 participants
|
75 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Total, Latin America (n=978,1518,420)
|
41 participants
|
85 participants
|
34 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Other, Latin America (n=28,22,7)
|
2 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G1, Latin America (n=500,930,272)
|
31 participants
|
74 participants
|
32 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G2, Asia (n=126,160,37)
|
4 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G2, Europe (n=126,160,37)
|
111 participants
|
144 participants
|
36 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G3, Asia (n=232,277,65)
|
45 participants
|
52 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
G3, Europe (n=232,277,65)
|
177 participants
|
200 participants
|
55 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=490 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=914 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=296 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Asia (n=295,703,239)
|
83 participants
|
13 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Middle East (n=295,703,239)
|
17 participants
|
87 participants
|
30 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Latin America (n=295,703,239)
|
21 participants
|
69 participants
|
23 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Asia (n=92,38,11)
|
59 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Middle East (n=92,38,11)
|
2 participants
|
1 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Latin America (n=92,38,11)
|
2 participants
|
1 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Middle East (n=63,84,20)
|
0 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Latin America (n=63,84,20)
|
2 participants
|
6 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Asia (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Europe (n=26,67,21)
|
14 participants
|
36 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Latin America (n=14,22,5)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Asia (n=490,914,296)
|
155 participants
|
36 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Europe (n=490,914,296)
|
275 participants
|
664 participants
|
222 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Middle East (n=490,914,296)
|
33 participants
|
135 participants
|
43 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Europe (n=295,703,239)
|
174 participants
|
534 participants
|
186 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Europe (n=92,38,11)
|
29 participants
|
28 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Asia (n=63,84,20)
|
9 participants
|
14 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Europe (n=63,84,20)
|
52 participants
|
61 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Middle East (n=26,67,21)
|
12 participants
|
29 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Latin America (n=26,67,21)
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Asia (n=14,22,5)
|
4 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Europe (n=14,22,5)
|
6 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Middle East (n=14,22,5)
|
2 participants
|
15 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Latin America (n=490,914,296)
|
27 participants
|
79 participants
|
27 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1598 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1147 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=171 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G1, Middle East (n=837,747,118)
|
138 participants
|
130 participants
|
21 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G1, Latin America (n=837,747,118)
|
48 participants
|
68 participants
|
21 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G2, Asia (n=198,113,12)
|
4 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G2, Europe (n=198,113,12)
|
174 participants
|
106 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G2, Middle East (n=198,113,12)
|
15 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G2, Latin America (n=198,113,12)
|
5 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G3, Asia (n=361,186,27)
|
67 participants
|
33 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G3, Europe (n=361,186,27)
|
275 participants
|
135 participants
|
22 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G3, Middle East (n=361,186,27)
|
17 participants
|
13 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G3, Latin America (n=361,186,27)
|
2 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G4, Europe (n=165,85,10)
|
77 participants
|
46 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G4, Middle East (n=165,85,10)
|
85 participants
|
37 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G4, Latin America (n=165,85,10)
|
3 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Other, Europe (n=37,16,4)
|
11 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Other, Middle East (n=37,16,4)
|
9 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Total, Asia (n=1598,1147,171)
|
104 participants
|
43 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Total, Europe (n=1598,1147,171)
|
1169 participants
|
834 participants
|
116 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Total, Middle East (n=1598,1147,171)
|
264 participants
|
193 participants
|
28 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Total, Latin America (n=1598,1147,171)
|
61 participants
|
77 participants
|
22 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G1, Asia (n=837,747,118)
|
19 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G1, Europe (n=837,747,118)
|
632 participants
|
543 participants
|
76 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
G4, Asia (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Other, Asia (n=37,16,4)
|
14 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Other, Latin America (n=37,16,4)
|
3 participants
|
1 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=851 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=730 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=119 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Asia (n=563,574,100)
|
87 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Europe (n=563,574,100)
|
378 participants
|
442 participants
|
74 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Middle East (n=563,574,100)
|
59 participants
|
62 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Asia (n=93,65,9)
|
12 participants
|
11 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Europe (n=93,65,9)
|
76 participants
|
47 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Middle East (n=93,65,9)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Latin America (n=93,65,9)
|
4 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Asia (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Europe (n=71,43,0)
|
41 participants
|
23 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Middle East (n=71,43,0)
|
29 participants
|
19 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Latin America (n=71,43,0)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Europe (n=17,21,3)
|
6 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Middle East (n=17,21,3)
|
5 participants
|
13 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Latin America (n=17,21,3)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Asia (n=851,730,119)
|
164 participants
|
27 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Europe (n=851,730,119)
|
541 participants
|
537 participants
|
83 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Middle East (n=851,730,119)
|
97 participants
|
98 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Latin America (n=851,730,119)
|
49 participants
|
68 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Latin America (n=563,574,100)
|
39 participants
|
61 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Asia (n=107,27,7)
|
61 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Europe (n=107,27,7)
|
40 participants
|
19 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Middle East (n=107,27,7)
|
3 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Latin America (n=107,27,7)
|
3 participants
|
0 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Asia (n=17,21,3)
|
4 participants
|
1 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=978 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1518 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=420 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=500,930,272)
|
5 participants
|
7 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=500,930,272)
|
15 participants
|
41 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=500,930,272)
|
4 participants
|
10 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=500,930,272)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=500,930,272)
|
44 participants
|
70 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, France (n=500,930,272)
|
48 participants
|
76 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=500,930,272)
|
30 participants
|
54 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=500,930,272)
|
22 participants
|
35 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=500,930,272)
|
101 participants
|
167 participants
|
59 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=500,930,272)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=500,930,272)
|
5 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=500,930,272)
|
16 participants
|
46 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=500,930,272)
|
4 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=500,930,272)
|
14 participants
|
35 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=500,930,272)
|
11 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=500,930,272)
|
60 participants
|
121 participants
|
34 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=500,930,272)
|
12 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=500,930,272)
|
5 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=500,930,272)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=500,930,272)
|
2 participants
|
6 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=500,930,272)
|
3 participants
|
9 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=126,160,37)
|
4 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, France (n=126,160,37)
|
4 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=126,160,37)
|
3 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=126,160,37)
|
7 participants
|
6 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=126,160,37)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=126,160,37)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=232,277,65)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=232,277,65)
|
7 participants
|
14 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=500,930,272)
|
4 participants
|
16 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=500,930,272)
|
12 participants
|
15 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=500,930,272)
|
5 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=500,930,272)
|
2 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=500,930,272)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=500,930,272)
|
54 participants
|
138 participants
|
51 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=500,930,272)
|
12 participants
|
13 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=500,930,272)
|
2 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=500,930,272)
|
5 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=126,160,37)
|
3 participants
|
7 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=232,277,65)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=232,277,65)
|
4 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=232,277,65)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=126,160,37)
|
3 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=126,160,37)
|
81 participants
|
117 participants
|
30 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=126,160,37)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=126,160,37)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=232,277,65)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=232,277,65)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=126,160,37)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=126,160,37)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=126,160,37)
|
6 participants
|
11 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=126,160,37)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=126,160,37)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=126,160,37)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=126,160,37)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=232,277,65)
|
5 participants
|
8 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=232,277,65)
|
2 participants
|
6 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=232,277,65)
|
5 participants
|
5 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=232,277,65)
|
4 participants
|
7 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=232,277,65)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=232,277,65)
|
1 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=232,277,65)
|
9 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=232,277,65)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=232,277,65)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=232,277,65)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=232,277,65)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=232,277,65)
|
27 participants
|
25 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, France (n=232,277,65)
|
4 participants
|
14 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=232,277,65)
|
22 participants
|
26 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=232,277,65)
|
70 participants
|
70 participants
|
22 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=232,277,65)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=232,277,65)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=232,277,65)
|
2 participants
|
7 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=232,277,65)
|
15 participants
|
12 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=232,277,65)
|
6 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=232,277,65)
|
0 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=232,277,65)
|
0 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=232,277,65)
|
45 participants
|
52 participants
|
8 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=978 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1518 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=420 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=92,129,39)
|
1 participants
|
8 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=92,129,39)
|
28 participants
|
28 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=92,129,39)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, France (n=92,129,39)
|
4 participants
|
11 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=92,129,39)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=92,129,39)
|
5 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=92,129,39)
|
1 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=92,129,39)
|
1 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=92,129,39)
|
4 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=978,1518,420)
|
28 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=978,1518,420)
|
74 participants
|
172 participants
|
56 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=978,1518,420)
|
14 participants
|
19 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=978,1518,420)
|
12 participants
|
17 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=978,1518,420)
|
10 participants
|
10 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=978,1518,420)
|
6 participants
|
10 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=978,1518,420)
|
8 participants
|
11 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=92,129,39)
|
1 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=92,129,39)
|
25 participants
|
33 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=92,129,39)
|
7 participants
|
15 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Pakistan (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=28,22,7)
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=28,22,7)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=28,22,7)
|
13 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=28,22,7)
|
5 participants
|
10 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=28,22,7)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=28,22,7)
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=978,1518,420)
|
7 participants
|
10 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=978,1518,420)
|
33 participants
|
60 participants
|
18 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=978,1518,420)
|
4 participants
|
10 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=978,1518,420)
|
28 participants
|
28 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=978,1518,420)
|
74 participants
|
102 participants
|
19 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, France (n=978,1518,420)
|
62 participants
|
108 participants
|
24 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=978,1518,420)
|
41 participants
|
71 participants
|
18 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=978,1518,420)
|
52 participants
|
70 participants
|
23 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=978,1518,420)
|
277 participants
|
389 participants
|
125 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=978,1518,420)
|
2 participants
|
5 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=978,1518,420)
|
5 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=978,1518,420)
|
14 participants
|
40 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=978,1518,420)
|
38 participants
|
64 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=978,1518,420)
|
18 participants
|
24 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=978,1518,420)
|
6 participants
|
18 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=978,1518,420)
|
2 participants
|
8 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=978,1518,420)
|
50 participants
|
60 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=978,1518,420)
|
16 participants
|
36 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=978,1518,420)
|
17 participants
|
19 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=978,1518,420)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=978,1518,420)
|
61 participants
|
122 participants
|
34 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=978,1518,420)
|
7 participants
|
16 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=92,129,39)
|
0 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=92,129,39)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=92,129,39)
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=92,129,39)
|
10 participants
|
7 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=92,129,39)
|
3 participants
|
3 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=92,129,39)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=28,22,7)
|
4 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, France (n=28,22,7)
|
2 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=28,22,7)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=28,22,7)
|
0 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=28,22,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=28,22,7)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=978,1518,420)
|
11 participants
|
8 participants
|
1 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=490 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=914 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=296 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=295,703,239)
|
4 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=295,703,239)
|
14 participants
|
37 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=295,703,239)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=295,703,239)
|
3 participants
|
2 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=295,703,239)
|
2 participants
|
14 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=295,703,239)
|
8 participants
|
43 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=92,38,11)
|
2 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=92,38,11)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=92,38,11)
|
59 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=92,38,11)
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=63,84,20)
|
1 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=63,84,20)
|
3 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=63,84,20)
|
1 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=63,84,20)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=295,703,239)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=295,703,239)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=295,703,239)
|
2 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=295,703,239)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=295,703,239)
|
0 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=295,703,239)
|
2 participants
|
8 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, France (n=92,38,11)
|
9 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=92,38,11)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=92,38,11)
|
18 participants
|
16 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=92,38,11)
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=295,703,239)
|
7 participants
|
16 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, France (n=295,703,239)
|
41 participants
|
125 participants
|
44 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=295,703,239)
|
16 participants
|
36 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=295,703,239)
|
4 participants
|
18 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=295,703,239)
|
40 participants
|
117 participants
|
46 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=295,703,239)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=295,703,239)
|
6 participants
|
41 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=295,703,239)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=295,703,239)
|
3 participants
|
18 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=295,703,239)
|
1 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=295,703,239)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=295,703,239)
|
5 participants
|
18 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=295,703,239)
|
13 participants
|
17 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=295,703,239)
|
2 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=295,703,239)
|
23 participants
|
80 participants
|
25 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=295,703,239)
|
81 participants
|
11 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=295,703,239)
|
12 participants
|
59 participants
|
23 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=295,703,239)
|
2 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=63,84,20)
|
8 participants
|
14 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=63,84,20)
|
11 participants
|
4 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=63,84,20)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=63,84,20)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=63,84,20)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=92,38,11)
|
2 participants
|
1 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=92,38,11)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, France (n=63,84,20)
|
12 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=63,84,20)
|
3 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=63,84,20)
|
2 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=63,84,20)
|
15 participants
|
14 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=63,84,20)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=63,84,20)
|
5 participants
|
14 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=63,84,20)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=63,84,20)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=63,84,20)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=63,84,20)
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=490 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=914 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=296 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=14,22,5)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=14,22,5)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=14,22,5)
|
3 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=14,22,5)
|
2 participants
|
14 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=14,22,5)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=490,914,296)
|
5 participants
|
13 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=490,914,296)
|
21 participants
|
47 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=490,914,296)
|
8 participants
|
19 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=490,914,296)
|
10 participants
|
26 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=490,914,296)
|
3 participants
|
2 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, France (n=490,914,296)
|
68 participants
|
162 participants
|
54 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=490,914,296)
|
21 participants
|
41 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=490,914,296)
|
7 participants
|
27 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=490,914,296)
|
76 participants
|
157 participants
|
56 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=490,914,296)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=14,22,5)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=490,914,296)
|
6 participants
|
43 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=14,22,5)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=490,914,296)
|
3 participants
|
18 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=490,914,296)
|
15 participants
|
57 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=490,914,296)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=490,914,296)
|
4 participants
|
20 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=490,914,296)
|
1 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=490,914,296)
|
11 participants
|
17 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=490,914,296)
|
6 participants
|
19 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=490,914,296)
|
28 participants
|
27 participants
|
12 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=490,914,296)
|
2 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=490,914,296)
|
23 participants
|
80 participants
|
25 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=490,914,296)
|
144 participants
|
19 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=490,914,296)
|
17 participants
|
75 participants
|
29 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=490,914,296)
|
3 participants
|
15 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=490,914,296)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=490,914,296)
|
2 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=490,914,296)
|
2 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=490,914,296)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=490,914,296)
|
0 participants
|
7 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=490,914,296)
|
4 participants
|
8 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=26,67,21)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=26,67,21)
|
10 participants
|
25 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, France (n=26,67,21)
|
4 participants
|
13 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=26,67,21)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=26,67,21)
|
1 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=26,67,21)
|
3 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=26,67,21)
|
1 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Pakistan (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=26,67,21)
|
3 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=26,67,21)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=26,67,21)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=26,67,21)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=14,22,5)
|
3 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, France (n=14,22,5)
|
2 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=14,22,5)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=14,22,5)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=26,67,21)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=26,67,21)
|
1 participants
|
4 participants
|
6 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1598 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1147 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=171 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=198,113,12)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=361,186,27)
|
9 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=361,186,27)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=361,186,27)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, France (n=837,747,118)
|
82 participants
|
53 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=837,747,118)
|
50 participants
|
45 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=837,747,118)
|
35 participants
|
29 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=837,747,118)
|
160 participants
|
139 participants
|
28 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=837,747,118)
|
7 participants
|
7 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=837,747,118)
|
32 participants
|
32 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=837,747,118)
|
9 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=837,747,118)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=837,747,118)
|
62 participants
|
58 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=198,113,12)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=198,113,12)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=198,113,12)
|
7 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=198,113,12)
|
4 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=361,186,27)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, France (n=198,113,12)
|
7 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=198,113,12)
|
5 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=198,113,12)
|
5 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=361,186,27)
|
10 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=837,747,118)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=837,747,118)
|
6 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=837,747,118)
|
13 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=837,747,118)
|
37 participants
|
32 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=837,747,118)
|
18 participants
|
10 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=837,747,118)
|
5 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=837,747,118)
|
5 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=837,747,118)
|
7 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=837,747,118)
|
20 participants
|
31 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=837,747,118)
|
19 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=837,747,118)
|
2 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=837,747,118)
|
97 participants
|
102 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=837,747,118)
|
12 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=837,747,118)
|
110 participants
|
115 participants
|
18 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=361,186,27)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=361,186,27)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=837,747,118)
|
15 participants
|
12 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=361,186,27)
|
36 participants
|
22 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=837,747,118)
|
6 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, France (n=361,186,27)
|
8 participants
|
10 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=837,747,118)
|
8 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=837,747,118)
|
5 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=837,747,118)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=198,113,12)
|
128 participants
|
91 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=198,113,12)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=361,186,27)
|
13 participants
|
10 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=198,113,12)
|
9 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=361,186,27)
|
34 participants
|
21 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=198,113,12)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=198,113,12)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=361,186,27)
|
109 participants
|
43 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=198,113,12)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=361,186,27)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=361,186,27)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=361,186,27)
|
4 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=361,186,27)
|
22 participants
|
7 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=361,186,27)
|
12 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=361,186,27)
|
0 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=361,186,27)
|
2 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=361,186,27)
|
67 participants
|
33 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=198,113,12)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=361,186,27)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=361,186,27)
|
4 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=361,186,27)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=361,186,27)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=198,113,12)
|
13 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=361,186,27)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=361,186,27)
|
4 participants
|
5 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=361,186,27)
|
9 participants
|
2 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=361,186,27)
|
10 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=361,186,27)
|
2 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=361,186,27)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=837,747,118)
|
6 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=837,747,118)
|
7 participants
|
9 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=198,113,12)
|
6 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=198,113,12)
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=1598 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1147 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=171 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=165,85,10)
|
9 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Pakistan (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=37,16,4)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=1598,1147,171)
|
61 participants
|
45 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=1598,1147,171)
|
9 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=1598,1147,171)
|
7 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=1598,1147,171)
|
99 participants
|
102 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=1598,1147,171)
|
28 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=1598,1147,171)
|
11 participants
|
11 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=1598,1147,171)
|
15 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=1598,1147,171)
|
12 participants
|
7 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=1598,1147,171)
|
13 participants
|
11 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=165,85,10)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=165,85,10)
|
41 participants
|
16 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=165,85,10)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, France (n=165,85,10)
|
10 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=165,85,10)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=165,85,10)
|
6 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=165,85,10)
|
47 participants
|
21 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=165,85,10)
|
4 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=165,85,10)
|
13 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=165,85,10)
|
3 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=165,85,10)
|
9 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=165,85,10)
|
0 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=165,85,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=165,85,10)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=165,85,10)
|
14 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=165,85,10)
|
4 participants
|
4 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=165,85,10)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=37,16,4)
|
4 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=1598,1147,171)
|
33 participants
|
22 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, France (n=37,16,4)
|
4 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=37,16,4)
|
1 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=37,16,4)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=1598,1147,171)
|
68 participants
|
44 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=1598,1147,171)
|
30 participants
|
13 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=1598,1147,171)
|
6 participants
|
18 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=37,16,4)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=37,16,4)
|
2 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=37,16,4)
|
13 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=37,16,4)
|
8 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=37,16,4)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=37,16,4)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=37,16,4)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=1598,1147,171)
|
10 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=1598,1147,171)
|
41 participants
|
16 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=1598,1147,171)
|
105 participants
|
85 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, France (n=1598,1147,171)
|
111 participants
|
75 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=1598,1147,171)
|
70 participants
|
55 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=1598,1147,171)
|
80 participants
|
56 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=1598,1147,171)
|
445 participants
|
295 participants
|
51 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=1598,1147,171)
|
5 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=1598,1147,171)
|
7 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=1598,1147,171)
|
76 participants
|
37 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=1598,1147,171)
|
23 participants
|
31 participants
|
10 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=1598,1147,171)
|
27 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=1598,1147,171)
|
2 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=1598,1147,171)
|
149 participants
|
133 participants
|
20 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=1598,1147,171)
|
19 participants
|
17 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=1598,1147,171)
|
15 participants
|
11 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=1598,1147,171)
|
21 participants
|
8 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=851 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=730 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=119 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=563,574,100)
|
6 participants
|
7 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=563,574,100)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=563,574,100)
|
2 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=563,574,100)
|
8 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=107,27,7)
|
22 participants
|
12 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=107,27,7)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=563,574,100)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=563,574,100)
|
3 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=563,574,100)
|
28 participants
|
27 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=563,574,100)
|
11 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=563,574,100)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=563,574,100)
|
4 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, France (n=563,574,100)
|
80 participants
|
117 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=563,574,100)
|
33 participants
|
29 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=563,574,100)
|
11 participants
|
14 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=563,574,100)
|
88 participants
|
98 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=563,574,100)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=563,574,100)
|
22 participants
|
33 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=563,574,100)
|
9 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=563,574,100)
|
27 participants
|
30 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=563,574,100)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=563,574,100)
|
6 participants
|
17 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=563,574,100)
|
5 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=563,574,100)
|
3 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=563,574,100)
|
8 participants
|
16 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=563,574,100)
|
23 participants
|
11 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=563,574,100)
|
5 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=563,574,100)
|
51 participants
|
66 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=563,574,100)
|
84 participants
|
8 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=563,574,100)
|
37 participants
|
46 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=563,574,100)
|
7 participants
|
9 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=563,574,100)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, France (n=107,27,7)
|
15 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, France (n=93,65,9)
|
18 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=107,27,7)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=107,27,7)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=107,27,7)
|
2 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=107,27,7)
|
61 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=107,27,7)
|
3 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=107,27,7)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=107,27,7)
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=93,65,9)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=93,65,9)
|
4 participants
|
3 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=93,65,9)
|
2 participants
|
1 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=93,65,9)
|
4 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=93,65,9)
|
2 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=93,65,9)
|
22 participants
|
11 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=93,65,9)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=93,65,9)
|
11 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=93,65,9)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=93,65,9)
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=93,65,9)
|
11 participants
|
11 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=93,65,9)
|
13 participants
|
4 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=93,65,9)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=93,65,9)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=93,65,9)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=93,65,9)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=93,65,9)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=93,65,9)
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=851 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=730 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=119 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=71,43,0)
|
8 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=851,730,119)
|
140 participants
|
128 participants
|
21 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=851,730,119)
|
5 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=851,730,119)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=851,730,119)
|
10 participants
|
8 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=851,730,119)
|
26 participants
|
16 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=851,730,119)
|
4 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, France (n=851,730,119)
|
129 participants
|
141 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=851,730,119)
|
39 participants
|
33 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=71,43,0)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=71,43,0)
|
10 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=71,43,0)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=71,43,0)
|
26 participants
|
15 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, France (n=71,43,0)
|
14 participants
|
8 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=71,43,0)
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=71,43,0)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=71,43,0)
|
1 participants
|
4 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Pakistan (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=71,43,0)
|
5 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=71,43,0)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=71,43,0)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=71,43,0)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=17,21,3)
|
3 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, France (n=17,21,3)
|
2 participants
|
3 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=17,21,3)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=17,21,3)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=17,21,3)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=17,21,3)
|
1 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=17,21,3)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=17,21,3)
|
3 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=17,21,3)
|
5 participants
|
12 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=17,21,3)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=17,21,3)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=851,730,119)
|
9 participants
|
9 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=851,730,119)
|
45 participants
|
33 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=851,730,119)
|
15 participants
|
23 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=851,730,119)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=851,730,119)
|
23 participants
|
34 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=851,730,119)
|
10 participants
|
14 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=851,730,119)
|
40 participants
|
39 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=851,730,119)
|
1 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=851,730,119)
|
8 participants
|
19 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=851,730,119)
|
15 participants
|
13 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=851,730,119)
|
13 participants
|
15 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=851,730,119)
|
9 participants
|
17 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=851,730,119)
|
42 participants
|
20 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=851,730,119)
|
5 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=851,730,119)
|
51 participants
|
66 participants
|
11 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=851,730,119)
|
149 participants
|
14 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=851,730,119)
|
47 participants
|
60 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=851,730,119)
|
8 participants
|
11 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=851,730,119)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=851,730,119)
|
2 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=851,730,119)
|
2 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=851,730,119)
|
4 participants
|
4 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=978 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=1518 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=420 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive
Naive: IL28B rs8099917 TT
|
974 participants
|
550 participants
|
74 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive
Naive: IL28B rs8099917 TG
|
4 participants
|
965 participants
|
178 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive
Naive: IL28B rs8099917 GG
|
0 participants
|
3 participants
|
168 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine IL28B genotype.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=490 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=914 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=296 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced
Experienced: IL28B rs8099917 TT
|
489 participants
|
314 participants
|
48 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced
Experienced: IL28B rs8099917 TG
|
1 participants
|
597 participants
|
132 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced
Experienced: IL28B rs8099917 GG
|
0 participants
|
3 participants
|
116 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=36 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=491 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=2389 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive
Naive: ITPA rs1127354 AA
|
0 participants
|
0 participants
|
11 participants
|
|
Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive
Naive: ITPA rs1127354 Cysteine-Alanine (CA)
|
0 participants
|
34 participants
|
343 participants
|
|
Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive
Naive: ITPA rs1127354 CC
|
36 participants
|
457 participants
|
2035 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=18 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=269 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1411 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced
Experienced: ITPA rs1127354 AA
|
0 participants
|
0 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced
Experienced: ITPA rs1127354 CA
|
0 participants
|
23 participants
|
211 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced
Experienced: ITPA rs1127354 CC
|
18 participants
|
246 participants
|
1185 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=11 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=377 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=2528 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G1, Asia (n=9,212,1481)
|
0 participants
|
8 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G1, Europe (n=9,212,1481)
|
7 participants
|
167 participants
|
1077 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G1, Middle East (n=9,212,1481)
|
2 participants
|
32 participants
|
255 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G2, Asia (n=0,45,278)
|
0 participants
|
3 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G2, Europe (n=0,45,278)
|
0 participants
|
37 participants
|
254 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G2, Middle East (n=0,45,278)
|
0 participants
|
3 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G2, Latin America (n=0,45,278)
|
0 participants
|
2 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G3, Asia (n=1,83,490)
|
0 participants
|
17 participants
|
88 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G3, Europe (n=1,83,490)
|
1 participants
|
62 participants
|
369 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G3, Middle East (n=1,83,490)
|
0 participants
|
3 participants
|
27 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G3, Latin America (n=1,83,490)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G4, Asia (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G4, Europe (n=0,30,230)
|
0 participants
|
16 participants
|
112 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G4, Middle East (n=0,30,230)
|
0 participants
|
14 participants
|
113 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G4, Latin America (n=0,30,230)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Other, Asia (n=1,7,49)
|
1 participants
|
2 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Other, Latin America (n=1,7,49)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Total, Asia (n=11,377,2528)
|
1 participants
|
30 participants
|
121 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Total, Europe (n=11,377,2528)
|
8 participants
|
284 participants
|
1827 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Total, Middle East (n=11,377,2528)
|
2 participants
|
55 participants
|
428 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Other, Europe (n=1,7,49)
|
0 participants
|
2 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Other, Middle East (n=1,7,49)
|
0 participants
|
3 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Total, Latin America (n=11,377,2528)
|
0 participants
|
8 participants
|
152 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
G1, Latin America (n=9,212,1481)
|
0 participants
|
5 participants
|
132 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=15 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=235 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1449 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Europe (n=10,169,1057)
|
8 participants
|
117 participants
|
768 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Middle East (n=10,169,1057)
|
0 participants
|
16 participants
|
118 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Latin America (n=10,169,1057)
|
0 participants
|
9 participants
|
104 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Asia (n=3,30,108)
|
2 participants
|
21 participants
|
45 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Middle East (n=3,30,108)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Latin America (n=3,30,108)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Asia (n=2,26,139)
|
1 participants
|
4 participants
|
21 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Asia (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Europe (n=0,5,109)
|
0 participants
|
2 participants
|
62 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Asia (n=0,5,36)
|
0 participants
|
1 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Europe (n=15,235,1449)
|
10 participants
|
149 participants
|
1001 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Middle East (n=15,235,1449)
|
0 participants
|
22 participants
|
189 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Asia (n=10,169,1057)
|
2 participants
|
27 participants
|
67 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Europe (n=3,30,108)
|
1 participants
|
9 participants
|
53 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Europe (n=2,26,139)
|
1 participants
|
20 participants
|
107 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Middle East (n=2,26,139)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Latin America (n=2,26,139)
|
0 participants
|
2 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Middle East (n=0,5,109)
|
0 participants
|
3 participants
|
45 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Latin America (n=0,5,109)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Europe (n=0,5,36)
|
0 participants
|
1 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Middle East (n=0,5,36)
|
0 participants
|
3 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Latin America (n=0,5,36)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Asia (n=15,235,1449)
|
5 participants
|
53 participants
|
137 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Latin America (n=15,235,1449)
|
0 participants
|
11 participants
|
122 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=36 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=491 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=2389 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G1, Asia (n=17,300,1385)
|
0 participants
|
0 participants
|
25 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G1, Europe (n=17,300,1385)
|
14 participants
|
230 participants
|
1007 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G1, Middle East (n=17,300,1385)
|
1 participants
|
50 participants
|
238 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G2, Asia (n=6,56,261)
|
0 participants
|
0 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G2, Europe (n=6,56,261)
|
6 participants
|
51 participants
|
234 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G2, Middle East (n=6,56,261)
|
0 participants
|
3 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G2, Latin America (n=6,56,261)
|
0 participants
|
2 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G3, Asia (n=9,81,484)
|
0 participants
|
7 participants
|
98 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G3, Europe (n=9,81,484)
|
9 participants
|
69 participants
|
354 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G3, Latin America (n=9,81,484)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G4, Asia (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Other, Asia (n=1,3,53)
|
0 participants
|
0 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Other, Europe (n=1,3,53)
|
1 participants
|
2 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Other, Middle East (n=1,3,53)
|
0 participants
|
1 participants
|
19 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Other, Latin America (n=1,3,53)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Total, Asia (n=36,491,2389)
|
0 participants
|
7 participants
|
145 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Total, Europe (n=36,491,2389)
|
30 participants
|
385 participants
|
1704 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Total, Middle East (n=36,491,2389)
|
4 participants
|
74 participants
|
407 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Total, Latin America (n=36,491,2389)
|
2 participants
|
25 participants
|
133 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G1, Latin America (n=17,300,1385)
|
2 participants
|
20 participants
|
115 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G3, Middle East (n=9,81,484)
|
0 participants
|
4 participants
|
26 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G4, Europe (n=3,51,206)
|
0 participants
|
33 participants
|
95 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G4, Middle East (n=3,51,206)
|
3 participants
|
16 participants
|
108 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
G4, Latin America (n=3,51,206)
|
0 participants
|
2 participants
|
3 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=18 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=270 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1411 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Latin America (n=1,9,130)
|
0 participants
|
1 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Asia (n=2,18,147)
|
0 participants
|
0 participants
|
26 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Europe (n=2,18,147)
|
2 participants
|
16 participants
|
110 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Middle East (n=1,22,91)
|
0 participants
|
6 participants
|
42 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Latin America (n=1,22,91)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Asia (n=0,7,34)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Middle East (n=18,270,1411)
|
1 participants
|
32 participants
|
178 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Asia (n=18,270,1411)
|
0 participants
|
0 participants
|
194 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Asia (n=1,9,130)
|
0 participants
|
0 participants
|
67 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Europe (n=1,9,130)
|
0 participants
|
8 participants
|
55 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G2, Middle East (n=1,9,130)
|
1 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Middle East (n=2,18,147)
|
0 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G3, Latin America (n=2,18,147)
|
0 participants
|
1 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Asia (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G4, Europe (n=1,22,91)
|
1 participants
|
16 participants
|
47 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Europe (n=0,7,34)
|
0 participants
|
3 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Middle East (n=0,7,34)
|
0 participants
|
4 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Other, Latin America (n=0,7,34)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Europe (n=18,270,1411)
|
16 participants
|
218 participants
|
927 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Total, Latin America (n=18,270,1411)
|
1 participants
|
20 participants
|
112 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Asia (n=14,214,1009)
|
0 participants
|
0 participants
|
96 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Europe (n=14,214,1009)
|
13 participants
|
175 participants
|
706 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Middle East (n=14,214,1009)
|
0 participants
|
21 participants
|
113 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
G1, Latin America (n=14,214,1009)
|
1 participants
|
18 participants
|
94 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=11 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=377 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=2528 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=0,45,278)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=0,45,278)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=9,212,1481)
|
0 participants
|
12 participants
|
57 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=9,212,1481)
|
0 participants
|
1 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=9,212,1481)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=9,212,1481)
|
0 participants
|
11 participants
|
114 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, France (n=9,212,1481)
|
1 participants
|
18 participants
|
121 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=9,212,1481)
|
2 participants
|
12 participants
|
86 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=9,212,1481)
|
1 participants
|
5 participants
|
62 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=9,212,1481)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=9,212,1481)
|
0 participants
|
1 participants
|
21 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=9,212,1481)
|
1 participants
|
11 participants
|
59 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=9,212,1481)
|
0 participants
|
0 participants
|
20 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=9,212,1481)
|
0 participants
|
2 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=9,212,1481)
|
0 participants
|
2 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=9,212,1481)
|
0 participants
|
3 participants
|
58 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=9,212,1481)
|
0 participants
|
32 participants
|
183 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=9,212,1481)
|
0 participants
|
6 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=9,212,1481)
|
1 participants
|
28 participants
|
214 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=9,212,1481)
|
0 participants
|
5 participants
|
23 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=9,212,1481)
|
0 participants
|
2 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=9,212,1481)
|
0 participants
|
1 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=9,212,1481)
|
1 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=9,212,1481)
|
0 participants
|
1 participants
|
21 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=0,45,278)
|
0 participants
|
2 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=0,45,278)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=0,45,278)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=0,45,278)
|
0 participants
|
29 participants
|
199 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=0,45,278)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=0,45,278)
|
0 participants
|
1 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=0,45,278)
|
0 participants
|
3 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=0,45,278)
|
0 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=1,83,490)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=1,83,490)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=1,83,490)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=1,83,490)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=1,83,490)
|
0 participants
|
17 participants
|
88 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=1,83,490)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=1,83,490)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=1,83,490)
|
0 participants
|
2 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=1,83,490)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=1,83,490)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=1,83,490)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=1,83,490)
|
0 participants
|
0 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=1,83,490)
|
0 participants
|
5 participants
|
26 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=1,83,490)
|
0 participants
|
3 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=9,212,1481)
|
0 participants
|
0 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=9,212,1481)
|
2 participants
|
45 participants
|
280 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=9,212,1481)
|
0 participants
|
3 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=9,212,1481)
|
0 participants
|
4 participants
|
22 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=9,212,1481)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=9,212,1481)
|
0 participants
|
0 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=9,212,1481)
|
0 participants
|
1 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=0,45,278)
|
0 participants
|
1 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, France (n=0,45,278)
|
0 participants
|
0 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=0,45,278)
|
0 participants
|
2 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=0,45,278)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=0,45,278)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=0,45,278)
|
0 participants
|
2 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=0,45,278)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=0,45,278)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=1,83,490)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=1,83,490)
|
0 participants
|
4 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=1,83,490)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=1,83,490)
|
0 participants
|
6 participants
|
52 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, France (n=1,83,490)
|
0 participants
|
1 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=1,83,490)
|
0 participants
|
4 participants
|
19 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=1,83,490)
|
0 participants
|
8 participants
|
50 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=1,83,490)
|
0 participants
|
26 participants
|
136 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=9,212,1481)
|
0 participants
|
6 participants
|
25 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=1,83,490)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=1,83,490)
|
0 participants
|
2 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=1,83,490)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=1,83,490)
|
0 participants
|
1 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=1,83,490)
|
1 participants
|
2 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=1,83,490)
|
0 participants
|
0 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=1,83,490)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=1,83,490)
|
0 participants
|
0 participants
|
1 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=11 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=377 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=2528 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=0,30,230)
|
0 participants
|
1 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=0,30,230)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=0,30,230)
|
0 participants
|
8 participants
|
63 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=0,30,230)
|
0 participants
|
0 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=0,30,230)
|
0 participants
|
2 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=0,30,230)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=0,30,230)
|
0 participants
|
2 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=0,30,230)
|
0 participants
|
2 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=0,30,230)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=1,7,49)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, France (n=1,7,49)
|
0 participants
|
0 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=1,7,49)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=1,7,49)
|
0 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=1,7,49)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=1,7,49)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=1,7,49)
|
1 participants
|
2 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=1,7,49)
|
0 participants
|
2 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=11,377,2528)
|
1 participants
|
38 participants
|
263 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=11,377,2528)
|
0 participants
|
2 participants
|
27 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=0,30,230)
|
0 participants
|
4 participants
|
54 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=0,30,230)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, France (n=0,30,230)
|
0 participants
|
3 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=0,30,230)
|
0 participants
|
2 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=0,30,230)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=0,30,230)
|
0 participants
|
1 participants
|
23 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Pakistan (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=0,30,230)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=1,7,49)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=0,30,230)
|
0 participants
|
4 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=0,30,230)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=1,7,49)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=1,7,49)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=1,7,49)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=11,377,2528)
|
0 participants
|
0 participants
|
21 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=11,377,2528)
|
0 participants
|
18 participants
|
93 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=11,377,2528)
|
0 participants
|
1 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=11,377,2528)
|
0 participants
|
4 participants
|
54 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=11,377,2528)
|
0 participants
|
19 participants
|
176 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, France (n=11,377,2528)
|
1 participants
|
22 participants
|
171 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=11,377,2528)
|
2 participants
|
16 participants
|
112 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=11,377,2528)
|
1 participants
|
16 participants
|
128 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=11,377,2528)
|
2 participants
|
109 participants
|
680 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=11,377,2528)
|
0 participants
|
2 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=11,377,2528)
|
0 participants
|
3 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=11,377,2528)
|
0 participants
|
4 participants
|
54 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=11,377,2528)
|
1 participants
|
19 participants
|
97 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=11,377,2528)
|
0 participants
|
9 participants
|
37 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=11,377,2528)
|
0 participants
|
1 participants
|
26 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=11,377,2528)
|
0 participants
|
2 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=11,377,2528)
|
0 participants
|
21 participants
|
97 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=11,377,2528)
|
0 participants
|
4 participants
|
60 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=11,377,2528)
|
0 participants
|
6 participants
|
36 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=11,377,2528)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=11,377,2528)
|
0 participants
|
32 participants
|
185 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=11,377,2528)
|
1 participants
|
9 participants
|
24 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=11,377,2528)
|
0 participants
|
6 participants
|
33 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=11,377,2528)
|
1 participants
|
6 participants
|
22 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=11,377,2528)
|
0 participants
|
1 participants
|
22 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=11,377,2528)
|
1 participants
|
2 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=11,377,2528)
|
0 participants
|
3 participants
|
19 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=11,377,2528)
|
0 participants
|
2 participants
|
28 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=15 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=235 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1449 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=10,169,1057)
|
0 participants
|
1 participants
|
25 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=10,169,1057)
|
0 participants
|
13 participants
|
114 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=10,169,1057)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=2,26,139)
|
0 participants
|
1 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=2,26,139)
|
0 participants
|
5 participants
|
29 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=2,26,139)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=10,169,1057)
|
0 participants
|
1 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=10,169,1057)
|
0 participants
|
8 participants
|
52 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=10,169,1057)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=10,169,1057)
|
1 participants
|
0 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, France (n=10,169,1057)
|
2 participants
|
23 participants
|
185 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=10,169,1057)
|
1 participants
|
8 participants
|
60 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=10,169,1057)
|
0 participants
|
6 participants
|
23 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=10,169,1057)
|
3 participants
|
23 participants
|
177 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=10,169,1057)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=10,169,1057)
|
0 participants
|
12 participants
|
50 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=10,169,1057)
|
0 participants
|
2 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=10,169,1057)
|
1 participants
|
12 participants
|
47 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=10,169,1057)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=10,169,1057)
|
0 participants
|
3 participants
|
24 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=10,169,1057)
|
0 participants
|
1 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=10,169,1057)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=10,169,1057)
|
0 participants
|
1 participants
|
29 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=10,169,1057)
|
0 participants
|
7 participants
|
31 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=10,169,1057)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=10,169,1057)
|
2 participants
|
26 participants
|
64 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=10,169,1057)
|
0 participants
|
12 participants
|
82 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=10,169,1057)
|
0 participants
|
2 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=10,169,1057)
|
0 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=10,169,1057)
|
0 participants
|
2 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=10,169,1057)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=10,169,1057)
|
0 participants
|
0 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=10,169,1057)
|
0 participants
|
3 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, France (n=3,30,108)
|
0 participants
|
2 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=3,30,108)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=3,30,108)
|
0 participants
|
5 participants
|
32 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=3,30,108)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=3,30,108)
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=3,30,108)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=3,30,108)
|
2 participants
|
21 participants
|
45 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=3,30,108)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=3,30,10)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=3,30,108)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=3,30,108)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=2,26,139)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=2,26,139)
|
1 participants
|
3 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=2,26,139)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, France (n=2,26,139)
|
0 participants
|
1 participants
|
26 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=2,26,139)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=2,26,139)
|
0 participants
|
5 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=2,26,139)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=2,26,139)
|
0 participants
|
1 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=2,26,139)
|
1 participants
|
3 participants
|
21 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=2,26,139)
|
0 participants
|
4 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=2,26,139)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=2,26,139)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=2,26,139)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=2,26,139)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=2,26,139)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=2,26,139)
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=15 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=235 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1449 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=15,235,1449)
|
0 participants
|
4 participants
|
28 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=15,235,1449)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=15,235,1449)
|
1 participants
|
5 participants
|
25 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=0,5,109)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=0,5,109)
|
0 participants
|
1 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=0,5,109)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=0,5,109)
|
0 participants
|
3 participants
|
38 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, France (n=0,5,109)
|
0 participants
|
0 participants
|
22 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=0,5,109)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=0,5,109)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=0,5,109)
|
0 participants
|
1 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=0,5,109)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Pakistan
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=0,5,109)
|
0 participants
|
0 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=0,5,109)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=0,5,109)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=0,5,109)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=0,5,36)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, France (n=0,5,36)
|
0 participants
|
1 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=0,5,36)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=0,5,36)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=0,5,36)
|
0 participants
|
1 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=0,5,36)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=0,5,36)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=0,5,36)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=0,5,36)
|
0 participants
|
3 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=0,5,36)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=0,5,36)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=15,235,1449)
|
0 participants
|
2 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=15,235,1449)
|
1 participants
|
12 participants
|
72 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=15,235,1449)
|
0 participants
|
1 participants
|
30 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=15,235,1449)
|
0 participants
|
3 participants
|
39 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=15,235,1449)
|
1 participants
|
0 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, France (n=15,235,1449)
|
2 participants
|
27 participants
|
255 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=15,235,1449)
|
1 participants
|
9 participants
|
69 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=15,235,1449)
|
0 participants
|
7 participants
|
35 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=15,235,1449)
|
3 participants
|
34 participants
|
252 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=15,235,1449)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=15,235,1449)
|
0 participants
|
12 participants
|
52 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=15,235,1449)
|
0 participants
|
2 participants
|
24 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=15,235,1449)
|
2 participants
|
19 participants
|
62 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=15,235,1449)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=15,235,1449)
|
0 participants
|
1 participants
|
31 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=15,235,1449)
|
0 participants
|
11 participants
|
56 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=15,235,1449)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=15,235,1449)
|
0 participants
|
13 participants
|
114 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=15,235,1449)
|
4 participants
|
48 participants
|
112 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=15,235,1449)
|
0 participants
|
15 participants
|
106 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=15,235,1449)
|
0 participants
|
2 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=15,235,1449)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=15,235,1449)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=15,235,1449)
|
0 participants
|
2 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=15,235,1449)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=15,235,1449)
|
0 participants
|
0 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=15,235,1449)
|
0 participants
|
3 participants
|
17 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=36 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=491 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=2389 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=9,81,484)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=6,56,261)
|
6 participants
|
40 participants
|
182 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=6,56,261)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=6,56,261)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=6,56,261)
|
0 participants
|
2 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=6,56,261)
|
0 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=6,56,261)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=6,56,261)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=6,56,261)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=6,56,261)
|
0 participants
|
3 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=6,56,261)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=6,56,261)
|
0 participants
|
1 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=6,56,261)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=9,81,484)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=9,81,484)
|
0 participants
|
4 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=9,81,484)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=9,81,484)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=9,81,484)
|
1 participants
|
11 participants
|
46 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, France (n=9,81,484)
|
0 participants
|
2 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=9,81,484)
|
2 participants
|
1 participants
|
20 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=9,81,484)
|
1 participants
|
7 participants
|
50 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=9,81,484)
|
4 participants
|
21 participants
|
137 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=9,81,484)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=9,81,484)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=9,81,484)
|
0 participants
|
3 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=9,81,484)
|
1 participants
|
8 participants
|
22 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=9,81,484)
|
0 participants
|
4 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=9,81,484)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=9,81,484)
|
0 participants
|
1 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=9,81,484)
|
0 participants
|
7 participants
|
98 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=9,81,484)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=9,81,484)
|
0 participants
|
3 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=9,81,484)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=9,81,484)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=9,81,484)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=9,81,484)
|
0 participants
|
0 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=9,81,484)
|
0 participants
|
3 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=9,81,484)
|
0 participants
|
4 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=9,81,484)
|
0 participants
|
1 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=9,81,484)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=9,81,484)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=9,81,484)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=17,300,1385)
|
0 participants
|
4 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=17,300,1385)
|
0 participants
|
10 participants
|
59 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=17,300,1385)
|
0 participants
|
3 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=17,300,1385)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=17,300,1385)
|
1 participants
|
20 participants
|
104 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, France (n=17,300,1385)
|
1 participants
|
29 participants
|
110 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=17,300,1385)
|
0 participants
|
13 participants
|
87 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=17,300,1385)
|
0 participants
|
7 participants
|
61 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=17,300,1385)
|
6 participants
|
57 participants
|
264 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=17,300,1385)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=17,300,1385)
|
0 participants
|
4 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=17,300,1385)
|
1 participants
|
7 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=17,300,1385)
|
0 participants
|
16 participants
|
55 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=17,300,1385)
|
0 participants
|
6 participants
|
25 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=17,300,1385)
|
0 participants
|
3 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=17,300,1385)
|
0 participants
|
0 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=17,300,1385)
|
0 participants
|
0 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=17,300,1385)
|
0 participants
|
3 participants
|
58 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=17,300,1385)
|
0 participants
|
8 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=17,300,1385)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=17,300,1385)
|
5 participants
|
43 participants
|
167 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=17,300,1385)
|
0 participants
|
0 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=17,300,1385)
|
0 participants
|
41 participants
|
202 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=17,300,1385)
|
0 participants
|
11 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=17,300,1385)
|
0 participants
|
2 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=17,300,1385)
|
0 participants
|
1 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=17,300,1385)
|
1 participants
|
3 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=17,300,1385)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=17,300,1385)
|
0 participants
|
2 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=17,300,1385)
|
2 participants
|
7 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=6,56,261)
|
0 participants
|
1 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=6,56,261)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=6,56,261)
|
0 participants
|
2 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, France (n=6,56,261)
|
0 participants
|
3 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=6,56,261)
|
0 participants
|
1 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=6,56,261)
|
0 participants
|
1 participants
|
6 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=36 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=491 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=2389 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=3,51,206)
|
0 participants
|
3 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=36,491,2389)
|
0 participants
|
10 participants
|
36 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=3,51,206)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=3,51,206)
|
0 participants
|
1 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=3,51,206)
|
2 participants
|
9 participants
|
47 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=3,51,206)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, France (n=3,51,206)
|
0 participants
|
4 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=3,51,206)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=3,51,206)
|
0 participants
|
20 participants
|
51 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=3,51,206)
|
0 participants
|
0 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=3,51,206)
|
1 participants
|
4 participants
|
19 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Pakistan (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=3,51,206)
|
0 participants
|
4 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=3,51,206)
|
0 participants
|
0 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=3,51,206)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=3,51,206)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=3,51,206)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=3,51,206)
|
0 participants
|
3 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=3,51,206)
|
0 participants
|
0 participants
|
10 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=3,51,206)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=1,3,53)
|
1 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, France (n=1,3,53)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=1,3,53)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=1,3,53)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=1,3,53)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=1,3,53)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=1,3,53)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=1,3,53)
|
0 participants
|
0 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=1,3,53)
|
0 participants
|
1 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=1,3,53)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=1,3,53)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=1,3,53)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=36,491,2389)
|
0 participants
|
6 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=36,491,2389)
|
1 participants
|
17 participants
|
93 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=36,491,2389)
|
0 participants
|
3 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=36,491,2389)
|
2 participants
|
9 participants
|
47 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=36,491,2389)
|
2 participants
|
33 participants
|
160 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, France (n=36,491,2389)
|
1 participants
|
39 participants
|
154 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=36,491,2389)
|
2 participants
|
16 participants
|
112 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=36,491,2389)
|
1 participants
|
18 participants
|
126 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=36,491,2389)
|
16 participants
|
138 participants
|
637 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=36,491,2389)
|
0 participants
|
0 participants
|
9 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=36,491,2389)
|
0 participants
|
4 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=36,491,2389)
|
2 participants
|
14 participants
|
42 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=36,491,2389)
|
1 participants
|
26 participants
|
90 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=36,491,2389)
|
0 participants
|
4 participants
|
23 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=36,491,2389)
|
0 participants
|
1 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=36,491,2389)
|
0 participants
|
7 participants
|
111 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=36,491,2389)
|
0 participants
|
3 participants
|
61 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=36,491,2389)
|
0 participants
|
15 participants
|
27 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=36,491,2389)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=36,491,2389)
|
5 participants
|
43 participants
|
169 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=36,491,2389)
|
0 participants
|
0 participants
|
34 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=36,491,2389)
|
0 participants
|
45 participants
|
257 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=36,491,2389)
|
0 participants
|
14 participants
|
25 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=36,491,2389)
|
0 participants
|
6 participants
|
23 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=36,491,2389)
|
0 participants
|
2 participants
|
27 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=36,491,2389)
|
1 participants
|
4 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=36,491,2389)
|
0 participants
|
3 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=36,491,2389)
|
0 participants
|
2 participants
|
20 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=36,491,2389)
|
2 participants
|
9 participants
|
19 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=18 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=270 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1411 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Germany (n=14,214,1009)
|
0 participants
|
19 participants
|
50 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lebanon (n=2,18,147)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Argentina (n=14,214,1009)
|
0 participants
|
6 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Belgium (n=14,214,1009)
|
0 participants
|
6 participants
|
54 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Chile (n=14,214,1009)
|
0 participants
|
4 participants
|
22 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Egypt (n=14,214,1009)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Estonia (n=14,214,1009)
|
0 participants
|
0 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, France (n=14,214,1009)
|
4 participants
|
49 participants
|
157 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Greece (n=14,214,1009)
|
0 participants
|
5 participants
|
24 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Italy (n=14,214,1009)
|
4 participants
|
41 participants
|
158 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Kuwait (n=14,214,1009)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Latvia (n=14,214,1009)
|
0 participants
|
11 participants
|
51 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lebanon (n=14,214,1009)
|
0 participants
|
2 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Lithuania (n=14,214,1009)
|
3 participants
|
9 participants
|
48 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Macedonia (n=14,214,1009)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Mexico (n=14,214,1009)
|
0 participants
|
3 participants
|
24 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Oman (n=14,214,1009)
|
0 participants
|
0 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Pakistan (n=14,214,1009)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Peru (n=14,214,1009)
|
0 participants
|
2 participants
|
28 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Portugal (n=14,214,1009)
|
1 participants
|
11 participants
|
26 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Qatar (n=14,214,1009)
|
0 participants
|
2 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Romania (n=14,214,1009)
|
1 participants
|
20 participants
|
107 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Taiwan (n=14,214,1009)
|
0 participants
|
0 participants
|
92 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Turkey (n=14,214,1009)
|
0 participants
|
16 participants
|
78 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Slovakia (n=14,214,1009)
|
0 participants
|
3 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Serbia (n=14,214,1009)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Sweden (n=14,214,1009)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Switzerland (n=14,214,1009)
|
0 participants
|
1 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Syria (n=14,214,1009)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, United Arab Emirates (n=14,214,1009)
|
0 participants
|
1 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G1, Venezuela (n=14,214,1009)
|
1 participants
|
3 participants
|
13 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Argentina (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Belgium (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Chile (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Egypt (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Estonia (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, France (n=1,9,130)
|
0 participants
|
3 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Germany (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Greece (n=1,9,130)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Italy (n=1,9,130)
|
0 participants
|
2 participants
|
35 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Kuwait (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Latvia (n=1,9,130)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lebanon (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Lithuania (n=1,9,130)
|
0 participants
|
2 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Macedonia (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Mexico (n=1,9,130)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Oman (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Pakistan (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Peru (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Portugal (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Qatar (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Romania (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Taiwan (n=1,9,130)
|
0 participants
|
0 participants
|
67 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Turkey (n=1,9,130)
|
1 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Slovakia (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Serbia (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Sweden (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Switzerland (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Syria (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, United Arab Emirates (n=1,9,130)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G2, Venezuela (n=1,9,130)
|
0 participants
|
1 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Argentina (n=2,18,147)
|
0 participants
|
1 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Belgium (n=2,18,147)
|
0 participants
|
1 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Chile (n=2,18,147)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Egypt (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Estonia (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, France (n=2,18,147)
|
1 participants
|
3 participants
|
23 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Germany (n=2,18,147)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Greece (n=2,18,147)
|
0 participants
|
1 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Italy (n=2,18,147)
|
1 participants
|
4 participants
|
29 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Kuwait (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Latvia (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Lithuania (n=2,18,147)
|
0 participants
|
2 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Macedonia (n=2,18,147)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Mexico (n=2,18,147)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Oman (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Pakistan (n=2,18,147)
|
0 participants
|
0 participants
|
25 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Peru (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Portugal (n=2,18,147)
|
0 participants
|
3 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Qatar (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Romania (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Taiwan (n=2,18,147)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Turkey (n=2,18,147)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Slovakia (n=2,18,147)
|
0 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Serbia (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Sweden (n=2,18,147)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Switzerland (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Syria (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, United Arab Emirates (n=2,18,147)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
G3, Venezuela (n=2,18,147)
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=18 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=270 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1411 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Taiwan (n=18,270,1411)
|
0 participants
|
0 participants
|
163 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Argentina (n=1,22,91)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Belgium (n=1,22,91)
|
0 participants
|
3 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Chile (n=1,22,91)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Egypt (n=1,22,91)
|
0 participants
|
5 participants
|
36 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Estonia (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, France (n=1,22,91)
|
0 participants
|
7 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Germany (n=1,22,91)
|
0 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Greece (n=1,22,91)
|
1 participants
|
1 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Italy (n=1,22,91)
|
0 participants
|
2 participants
|
12 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Kuwait (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Latvia (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lebanon (n=1,22,91)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Lithuania (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Macedonia (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Mexico (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Oman (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Pakistan (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Peru (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Portugal (n=1,22,91)
|
0 participants
|
2 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Qatar (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Romania (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Taiwan (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Turkey (n=1,22,91)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Slovakia (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Serbia (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Sweden (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Switzerland (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Syria (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, United Arab Emirates (n=1,22,91)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
G4, Venezuela (n=1,22,91)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Argentina (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Belgium (n=0,7,34)
|
0 participants
|
3 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Chile (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Egypt (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Estonia (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, France (n=0,7,34)
|
0 participants
|
0 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Germany (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Greece (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Italy (n=0,7,34)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Kuwait (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Latvia (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lebanon (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Lithuania (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Macedonia (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Mexico (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Oman (n=0,7,34)
|
0 participants
|
1 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Pakistan (n=0,7,34)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Peru (n=0,7,34)
|
0 participants
|
0 participants
|
2 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Portugal (n=0,7,34)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Qatar (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Romania (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Taiwan (n=0,7,34)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Turkey (n=0,7,34)
|
0 participants
|
3 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Slovakia (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Serbia (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Sweden (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Switzerland (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Syria (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, United Arab Emirates (n=0,7,34)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Other, Venezuela (n=0,7,34)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Argentina (n=18,270,1411)
|
0 participants
|
7 participants
|
11 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Belgium (n=18,270,1411)
|
0 participants
|
13 participants
|
72 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Chile (n=18,270,1411)
|
0 participants
|
4 participants
|
27 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Egypt (n=18,270,1411)
|
0 participants
|
5 participants
|
37 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Estonia (n=18,270,1411)
|
0 participants
|
0 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, France (n=18,270,1411)
|
5 participants
|
62 participants
|
217 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Germany (n=18,270,1411)
|
0 participants
|
21 participants
|
58 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Greece (n=18,270,1411)
|
1 participants
|
8 participants
|
33 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Italy (n=18,270,1411)
|
5 participants
|
49 participants
|
235 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Kuwait (n=18,270,1411)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Latvia (n=18,270,1411)
|
0 participants
|
11 participants
|
53 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lebanon (n=18,270,1411)
|
0 participants
|
3 participants
|
23 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Lithuania (n=18,270,1411)
|
3 participants
|
13 participants
|
67 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Macedonia (n=18,270,1411)
|
0 participants
|
0 participants
|
1 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Mexico (n=18,270,1411)
|
0 participants
|
3 participants
|
29 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Oman (n=18,270,1411)
|
0 participants
|
1 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Pakistan (n=18,270,1411)
|
0 participants
|
0 participants
|
31 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Peru (n=18,270,1411)
|
0 participants
|
2 participants
|
30 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Portugal (n=18,270,1411)
|
1 participants
|
16 participants
|
50 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Qatar (n=18,270,1411)
|
0 participants
|
2 participants
|
5 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Romania (n=18,270,1411)
|
1 participants
|
20 participants
|
107 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Turkey (n=18,270,1411)
|
1 participants
|
19 participants
|
101 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Slovakia (n=18,270,1411)
|
0 participants
|
4 participants
|
16 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Serbia (n=18,270,1411)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Sweden (n=18,270,1411)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Switzerland (n=18,270,1411)
|
0 participants
|
1 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Syria (n=18,270,1411)
|
0 participants
|
0 participants
|
0 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, United Arab Emirates (n=18,270,1411)
|
0 participants
|
2 participants
|
6 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Total, Venezuela (n=18,270,1411)
|
1 participants
|
4 participants
|
15 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types within the first 12 weeks of treatment included rapid virological response (RVR), complete early virological response (cEVR), and partial early virological response (pEVR). RVR was defined as an undetectable HCV RNA level within the first 4 weeks, cEVR as an undetectable level within the first 12 weeks, and pEVR as a 2-log drop from Baseline to 12 weeks. Undetectable viral loads include those below the lower limit of detection (LLOD) for the assay performed, which may vary from site to site. Response categories were mutually exclusive, meaning participants could only achieve cEVR/pEVR in the absence of RVR. Participants achieving neither RVR nor cEVR/pEVR were recorded as 'none of the above.'
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=346 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=705 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=227 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, RVR
|
41 participants
|
37 participants
|
13 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, cEVR
|
117 participants
|
199 participants
|
44 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, pEVR
|
27 participants
|
147 participants
|
62 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, None of above
|
41 participants
|
184 participants
|
73 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, RVR
|
46 participants
|
13 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, cEVR
|
9 participants
|
7 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, pEVR
|
2 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, None of above
|
4 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, RVR
|
20 participants
|
10 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, cEVR
|
10 participants
|
27 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, pEVR
|
2 participants
|
7 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, None of above
|
7 participants
|
13 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, RVR
|
11 participants
|
6 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, cEVR
|
4 participants
|
17 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, pEVR
|
0 participants
|
11 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, None of above
|
5 participants
|
20 participants
|
4 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types within the first 12 weeks of treatment included RVR, cEVR, and pEVR. RVR was defined as an undetectable HCV RNA level within the first 4 weeks, cEVR as an undetectable level within the first 12 weeks, and pEVR as a 2-log drop from Baseline to 12 weeks. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive, meaning participants could only achieve cEVR/pEVR in the absence of RVR. Participants achieving neither RVR nor cEVR/pEVR were recorded as 'none of the above.'
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=630 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=556 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=92 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, RVR
|
59 participants
|
23 participants
|
9 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, cEVR
|
205 participants
|
140 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, pEVR
|
88 participants
|
128 participants
|
20 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G1, None of above
|
92 participants
|
170 participants
|
36 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, RVR
|
50 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, cEVR
|
11 participants
|
6 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, pEVR
|
3 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G2, None of above
|
7 participants
|
2 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, RVR
|
23 participants
|
9 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, cEVR
|
23 participants
|
18 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, pEVR
|
3 participants
|
6 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G3, None of above
|
10 participants
|
10 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, RVR
|
17 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, cEVR
|
13 participants
|
12 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, pEVR
|
11 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
G4, None of above
|
15 participants
|
14 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types at the end of treatment included undetectable and detectable HCV RNA level. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=412 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=773 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=244 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G4, Undetectable
|
16 participants
|
29 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G4, Detectable
|
8 participants
|
32 participants
|
7 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G1, Undetectable
|
194 participants
|
297 participants
|
79 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G1, Detectable
|
62 participants
|
313 participants
|
125 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G2, Undetectable
|
73 participants
|
24 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G2, Detectable
|
5 participants
|
9 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G3, Undetectable
|
43 participants
|
48 participants
|
15 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G3, Detectable
|
11 participants
|
21 participants
|
1 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types at the end of treatment included undetectable and detectable HCV RNA level. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=718 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=614 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=97 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G4, Detectable
|
27 participants
|
20 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G1, Undetectable
|
326 participants
|
222 participants
|
22 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G1, Detectable
|
161 participants
|
279 participants
|
60 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G2, Undetectable
|
82 participants
|
18 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G2, Detectable
|
8 participants
|
6 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G3, Undetectable
|
59 participants
|
39 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G3, Detectable
|
18 participants
|
14 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
G4, Undetectable
|
37 participants
|
16 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Overall virological response types included sustained virological response (SVR), relapse, and breakthrough. SVR was defined as undetectable HCV RNA level at 24 weeks post-treatment, relapse as an undetectable level at end of treatment with a detectable level at the last post-treatment measurement, and breakthrough as an undetectable level at 1 or more treatment measurements with a detectable level at end of treatment. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive. Participants with detectable HCV RNA level at 12 or more treatment measurements and who did not meet SVR criteria were considered nonresponders, and those with insufficient treatment response data were recorded as 'none of the above.'
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=474 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=891 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=290 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G1, SVR
|
99 participants
|
72 participants
|
14 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G1, Relapse
|
95 participants
|
221 participants
|
63 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G1, Breakthrough
|
20 participants
|
63 participants
|
24 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G1, Nonresponder
|
43 participants
|
253 participants
|
92 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G1, None of above
|
37 participants
|
94 participants
|
45 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G2, SVR
|
61 participants
|
11 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G2, Relapse
|
15 participants
|
13 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G2, Breakthrough
|
1 participants
|
2 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G2, Nonresponder
|
2 participants
|
7 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G2, None of above
|
13 participants
|
5 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G3, SVR
|
23 participants
|
19 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G3, Relapse
|
19 participants
|
24 participants
|
8 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G3, Breakthrough
|
1 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G3, Nonresponder
|
10 participants
|
15 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G3, None of above
|
9 participants
|
21 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G4, SVR
|
8 participants
|
17 participants
|
4 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G4, Relapse
|
6 participants
|
13 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G4, Breakthrough
|
4 participants
|
8 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G4, Nonresponder
|
4 participants
|
21 participants
|
5 participants
|
|
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
G4, None of above
|
4 participants
|
7 participants
|
8 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Overall virological response types included SVR, relapse, and breakthrough. SVR was defined as undetectable HCV RNA level at 24 weeks post-treatment, relapse as an undetectable level at end of treatment with a detectable level at the last post-treatment measurement, and breakthrough as an undetectable level at 1 or more treatment measurements with a detectable level at end of treatment. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive. Participants with detectable HCV RNA level at 12 or more treatment measurements and who did not meet SVR criteria were considered nonresponders, and those with insufficient treatment response data were recorded as 'none of the above.'
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=831 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=709 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=115 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G1, SVR
|
133 participants
|
46 participants
|
6 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G1, Relapse
|
194 participants
|
168 participants
|
17 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G1, Breakthrough
|
42 participants
|
49 participants
|
16 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G1, Nonresponder
|
115 participants
|
232 participants
|
41 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G1, None of above
|
78 participants
|
79 participants
|
19 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G2, SVR
|
64 participants
|
9 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G2, Relapse
|
20 participants
|
10 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G2, Breakthrough
|
2 participants
|
1 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G2, Nonresponder
|
4 participants
|
5 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G2, None of above
|
17 participants
|
2 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G3, SVR
|
29 participants
|
15 participants
|
2 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G3, Relapse
|
27 participants
|
21 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G3, Breakthrough
|
3 participants
|
3 participants
|
1 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G3, Nonresponder
|
14 participants
|
12 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G3, None of above
|
19 participants
|
14 participants
|
3 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G4, SVR
|
21 participants
|
8 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G4, Relapse
|
14 participants
|
8 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G4, Breakthrough
|
8 participants
|
5 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G4, Nonresponder
|
16 participants
|
14 participants
|
0 participants
|
|
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
G4, None of above
|
11 participants
|
8 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype and hematology data were obtained from medical records. Participants with a history of a hemoglobin level less than 10 grams per deciliter (g/dL) or a drop of more than 3 g/dL at any time during prior treatment for CHC were recorded as 'yes' for this finding.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=14 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=185 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1112 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G1, Yes (n=9,133,810)
|
2 participants
|
35 participants
|
322 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G1, No (n=9,133,810)
|
7 participants
|
98 participants
|
488 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G2, Yes (n=3,27,89)
|
2 participants
|
9 participants
|
42 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G2, No (n=3,27,89)
|
1 participants
|
18 participants
|
47 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G3, Yes (n=2,20,105)
|
0 participants
|
1 participants
|
33 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G3, No (n=2,20,105)
|
2 participants
|
19 participants
|
72 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G4, Yes (n=0,2,85)
|
0 participants
|
0 participants
|
36 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G4, No (n=0,2,85)
|
0 participants
|
2 participants
|
49 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Other, Yes (n=0,3,23)
|
0 participants
|
1 participants
|
15 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Other, No (n=0,3,23)
|
0 participants
|
2 participants
|
8 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Total, Yes (n=14,185,1112)
|
4 participants
|
46 participants
|
448 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Total, No (n=14,185,1112)
|
10 participants
|
139 participants
|
664 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype and hematology data were obtained from medical records. Participants with a history of a hemoglobin level less than 10 g/dL or a drop of more than 3 g/dL at any time during prior treatment for CHC were recorded as 'yes' for this finding.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=13 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=205 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1092 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G1, Yes (n=10,159,783)
|
1 participants
|
49 participants
|
309 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G1, No (n=10,159,783)
|
9 participants
|
110 participants
|
474 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G2, Yes (n=0,8,110)
|
0 participants
|
1 participants
|
52 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G2, No (n=0,8,110)
|
0 participants
|
7 participants
|
58 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G3, Yes (n=2,14,111)
|
0 participants
|
3 participants
|
31 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G3, No (n=2,14,111)
|
2 participants
|
11 participants
|
80 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G4, Yes (n=1,19,67)
|
0 participants
|
3 participants
|
33 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
G4, No (n=1,19,67)
|
1 participants
|
16 participants
|
34 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Other, Yes (n=0,5,21)
|
0 participants
|
2 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Other, No (n=0,5,21)
|
0 participants
|
3 participants
|
7 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Total, Yes (n=13,205,1092)
|
1 participants
|
58 participants
|
439 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Total, No (n=13,205,1092)
|
12 participants
|
147 participants
|
653 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records. Past medication use was obtained from medical records and/or participant interview at the Study Visit. Participants with a history of erythropoietin use during prior treatment for CHC were recorded as 'yes' for this finding.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=15 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=225 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1388 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G1, Yes (n=10,162,1016)
|
1 participants
|
8 participants
|
103 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G3, No (n=2,24,137)
|
2 participants
|
24 participants
|
133 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G1, No (n=10,162,1016)
|
9 participants
|
154 participants
|
913 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G2, Yes (n=3,30,105)
|
0 participants
|
4 participants
|
14 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G2, No (n=3,30,105)
|
3 participants
|
26 participants
|
91 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G3, Yes (n=2,24,137)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G4, Yes (n=0,5,106)
|
0 participants
|
1 participants
|
18 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G4, No (n=0,5,106)
|
0 participants
|
4 participants
|
88 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Other, Yes (n=0,4,24)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Other, No (n=0,4,24)
|
0 participants
|
4 participants
|
21 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Total, Yes (n=15,225,1388)
|
1 participants
|
13 participants
|
142 participants
|
|
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Total, No (n=15,225,1388)
|
14 participants
|
212 participants
|
1246 participants
|
SECONDARY outcome
Timeframe: Study Visit 1Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records. Past medication use was obtained from medical records and/or participant interview at the Study Visit. Participants with a history of erythropoietin use during prior treatment for CHC were recorded as 'yes' for this finding.
Outcome measures
| Measure |
Naive: IL28B rs12979860 Cysteine-Cysteine (CC)
n=17 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'CC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Cysteine (TC)
n=257 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TC' confirmed by blood sampling.
|
Naive: IL28B rs12979860 Threonine-Threonine (TT)
n=1354 Participants
Treatment-naive participants with CHC with IL28B polymorphism rs12979860 'TT' confirmed by blood sampling.
|
|---|---|---|---|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Other, Yes (n=0,5,23)
|
0 participants
|
0 participants
|
3 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G1, Yes (n=14,206,969)
|
2 participants
|
19 participants
|
91 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G1, No (n=14,206,969)
|
12 participants
|
187 participants
|
878 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G2, Yes (n=0,9,128)
|
0 participants
|
0 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G2, No (n=0,9,128)
|
0 participants
|
9 participants
|
111 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G3, Yes (n=2,17,144)
|
0 participants
|
0 participants
|
4 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G3, No (n=2,17,144)
|
2 participants
|
17 participants
|
140 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G4, Yes (n=1,20,90)
|
0 participants
|
2 participants
|
17 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
G4, No (n=1,20,90)
|
1 participants
|
18 participants
|
73 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Other, No (n=0,5,23)
|
0 participants
|
5 participants
|
20 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Total, Yes (n=17,257,1354)
|
2 participants
|
21 participants
|
132 participants
|
|
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Total, No (n=17,257,1354)
|
15 participants
|
236 participants
|
1222 participants
|
Adverse Events
Participants With CHC
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER